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Tissue Engineering 
 
Tissue loss or end-stage organ failure resulting from an injury, disease or due to 
congenital defects are complex and costly health care problems [1]. The transplantation of 
tissues or organs is the current treatment which is severely limited by availability of 
compatible donors, shortage of donor tissue and immune rejection [2;3]. Another problem is 
that the host may need long-term immunosuppressive medication, with its increased risks of 
side effects [4]. Additionally, the risk of some viral infections such as AIDS and hepatitis is 
associated with transplantation of donor organs [5;6]. Also, the currently used alternatives 
such as artificial prostheses do not repair the tissue or organ function. Additionally, artificial 
prostheses may be subject to wear upon long-term implantation, and could induce 
inflammatory response in the host [7;8]. Therefore, tissue engineering is considered effective 
alternative to overcome the problems and limitations of current therapies, and to develop new 
substitutes to improve tissue function. 
 
Tissue engineering is an emerging field that aims to regenerate natural tissues and 
create new tissues using biological cells, biomaterials, biotechnology, and clinical medicine. 
It is an interdisciplinary field that applies the principles of engineering and the life sciences 
toward the development of biological substitutes that restore, maintain or improve tissue 
function [9]. The concept of tissue engineering includes that cells can be isolated from a 
patient, expanded in cell culture and seeded onto a carrier. The resulting tissue engineering 
construct is then grafted back into the same patient to function as the introduced replacement 
tissue. Tissue engineering promises a more advanced approach in which organs or tissues can 
be repaired, replaced, or regenerated for more targeted solutions. This approach also responds 
to clinical needs that cannot be met by organ donation alone. In other applications, for 
example tissue engineering may be used to develop predictive models for toxicity assessment. 
As research tools, these systems could also be employed as correlates of in vitro and in vivo 
biological activity.  
 
Since the early 1990s, the tissue engineering field has progressed rapidly and 
biological substitutes are in development for several tissues in the body. Tissue engineered 
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products such as bioartificial skin (Apligraf and TranCyte) and cultured autologous 
chondrocytes (Carticel) have reached the market. Scientists are now engineering 
cardiovascular tissues such as heart valves, and blood vessels [10-12]. Encapsulated 
pancreatic islets have been implanted in the patients for the treatment of diabetes [13] and 
liver assist systems containing encapsulated hepatocytes have been used clinically to provide 
extracorporeal support to the patients with liver failure [14]. A bioartificial bladder has been 
developed as a replacement engineered organ [15]. Significant progress has been made in 
orthopaedic tissue engineering for the repair of bone and cartilage [16-18]. 
 
Cartilage 
Cartilage and bone are specialized types of connective tissue and are made up of cells, 
and extracellular matrix (ECM). As connective tissues, they are derived from the 
mesenchyme of the embryo. Their functions are somewhat similar, but cartilage is more 
flexible and has less tensile strength than bone. Cartilage is a tissue that supports and protects 
soft tissues, provides a sliding surface in joints, and functions both in the development of long 
bones and in the repair of bone breakage. It fulfils its functions without nerves, blood supply, 
or lymphatic system. Its properties are, in fact, not due to the properties of its cells but of their 
secretions and of the secondary structuring of water. Cartilage is formed when mesenchymal 
cells aggregate and secrete intercellular material. There are two types of cartilage growth. 
I. Interstitial growth occurs when cartilage cells divide and subsequent chondrification occurs 
at this site. The trapped cells are termed chondrocytes. 
II. Appositional growth occurs when cartilage is added at the periphery of forming cartilage. 
Peripheral growth is carried out by cells of the perichondrium (a sheath surrounding the 
cartilage). The inner cells of the perichondrium give rise to new cartilage cells (Fig. 1). 
 
Composition and Anatomy of Cartilage 
Cells  
Chondroblasts are immature cells (“blasts”) which are actively synthesizing and 
depositing extracellular matrix materials and fibers but are not yet trapped by this matrix; they 
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differentiate from mesenchymal cells.  Chondrocytes are the mature cells of cartilage and are 
completely surrounded by cartilage matrix. Hence, they are trapped in small spaces called 
lacunae (Fig. 1) [19]. In humans, chondrocytes represent only about 1% of the volume of 
hyaline cartilage but are essential since it is these cells that replace degraded matrix molecules 
to maintain the correct size and mechanical properties of the tissue. Thus, microscopically, the 
cells' endoplasmic reticulum and Golgi apparatus are prominent [20]. 
 
 
 
 
         capsule 
Mesenchyme Chondroblasts     Chondrocyte       5 chondrocytes in lacuna Chondrogenic appositional growth 
Fig. 1: Chondrogenic interstitial and appositional growth. Cartilage is avascular, gets nutrients 
by diffusion 
 
Extracellular matrix (ECM)  
The ECM is composed mainly of collagen fibers and proteoglycans (Fig. 2). The 
dominant and typical collagen type of articular cartilage is type II (90-95%) [21;22], in 
addition there are small portions of types VI, IX, X, and XI. The ECM is mostly free of type I 
collagen (typical for bone tissue) [23]. Type II collagen content is vital because its 
concentration is directly related to the tensile strength of the tissue and it is a marker of the 
hyaline phenotype [24]. Type II collagen has a high amount of bound carbohydrate groups, 
allowing more interaction with water than some other types. Types IX and XI, along with 
type II, form fibrils that interweave to form a mesh. This organization provides tensile 
strength as well as physically entraps other macromolecules. Although the exact function of 
types IX and XI are unknown, type IX has been observed to bind superficially to the fibers 
and extending into the inter-fiber space to interact with other type IX molecules, possibly 
acting to stabilize the mesh structure (Fig. 2). Type X as a marker for hypertrophic 
chondrocytes is found only near areas of the matrix that are calcified [25;26]. 
 
Perichondrium 
Cartilage 
Chondrocyte 
chondroblast 
Chapter 1     Introduction 
 
 
__________________________________________________________________________________________ 
- 11 - 
Proteoglycans are composed of about 95% polysaccharide and about 5% protein. The 
protein core is associated with one or more varieties of glycosaminoglycan (GAG) chains. 
GAG chains are unbranched polysaccharides made from disaccharides of an amino sugar and 
another sugar. At least one component of the disaccharide has a negatively charged sulfate or 
carboxylate group, so the GAGs tend to repel each other and other anions while attracting 
cations and facilitating interaction with water. Hyaluronic acid, chondroitin sulfate, keratan 
sulfate, dermatan sulfate and heparan sulfate are some of the GAGs generally found in 
articular cartilage [20;26;27]. 
 
There are both large aggregating monomers and smaller proteoglycans present in 
articular cartilage. The aggregating proteoglycans, or aggrecans, are composed of monomers 
with keratan sulfate and chondroitin sulfate attached to the protein core. Aggrecans fill most 
of the interfibrillar space of the ECM and are thought to be responsible for much of the 
resilience and stress distribution in articular cartilage through their ability to attract water. 
There are no chemical bonds between the proteoglycans and collagen fibers; aggregation 
prevents diffusion of the proteoglycans out of the matrix during joint loading [20;25;26]. The 
smaller proteoglycans include decorin, biglycan and fibromodulin. They have shorter protein 
cores and fewer GAG chains than their larger counterparts. Unlike aggrecans, these molecules 
do not affect physical properties of the tissue, but are thought to play a role in cell function 
and organization of the collagen matrix [20]. 
  
In contrast to proteoglycans, glycoproteins have only a small amount of 
oligosaccharides associated with the protein core. These polypeptides help to stabilize the 
ECM matrix and aid in chondrocyte-matrix interactions. Other noncollagenous proteins 
commonly found in most tissues, such as fibronectin and tenascin, are also observed in 
articular cartilage and are believed to perform similar functions as the glycoproteins [20]. 
 
Tissue fluid is an essential part of hyaline cartilage, comprising up to 80% of the wet 
weight of the tissue. In addition to water, the fluid contains gases, metabolites and a large 
amount of cations to balance the negatively charged GAG's in the ECM. It is the exchange of 
this fluid with the synovial fluid that provides nutrients and oxygen to the avascular cartilage. 
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In addition, the entrapment of this fluid though interaction with ECM components provides 
the tissue with its ability to resist compression and return to normal shape after deformation 
[20;26]. 
 
 
 
 
Fig:  2: Illustration of extracellular matrix components of the 
cartilage 
Fig. 3: Hyaline cartilage 
 
Types of Cartilage  
• Hyaline cartilage has a white, smooth, glassy appearance, and unlike fibrocartilage, shows 
no macroscopic evidence of fibers (Fig. 3), this is the most widespread type of cartilage in 
the body, particularly in the fetus and infant. Most bones are formed by replacing a 
hyaline cartilage model with bone tissue. In the adult, hyaline cartilage exists in the 
larynx, trachea, bronchi, ribs, and on the articular surface of bones. A perichondrium is 
present except on articular surfaces. This cartilage may calcify with age. Hyaline cartilage 
provides stable movement with less friction than any prosthetic replacement, possesses 
properties such as resistance to compression and the ability to distribute loads that cannot 
be fully replaced by any other tissue or device designed to date [20;25].  
• Elastic cartilage differs from hyaline cartilage primarily in its high content of elastic fibers 
which impart resilience. It can be found in the external ear, auditory or eustachian tube, 
and epiglottis. A perichondrium is present. 
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• Fibrocartilage differs from hyaline cartilage in possessing prominent bundles of parallel 
collagen fibers (type I) which give this cartilage high tensile strength. Occasionally 
described as a “halfway tissue”, between cartilage and connective tissue proper, it arises 
when connective tissue is subjected to frictional forces. Consequently, it is the only 
cartilage type that is not surrounded by a perichondrium. It is found in the intervertebral 
discs and pubic symphysis. 
 
Cartilage tissue engineering 
The main functions of articular cartilage, which contains a small number of 
chondrocytes in an ECM mainly composed of water, collagen type II and proteoglycans are 
to cover the ends in bone in joints to provide frictionless movement and to distribute loads 
[28;29]. Articular cartilage damage and regeneration are a major health issue. Only in USA 
about 21 million suffer from osteoarthritis, degenerative joint disease. Cartilage has very 
limited capacity for regeneration and self-repair. Its poor ability for self-repair is due to the 
lack of blood supply and limited number of cells, and mature chondrocytes have a relatively 
low metabolic activity [20]. 
 
Articular cartilage defects are classified as being either partial- or full-thickness. 
Partial thickness defects demonstrate disruption of the cartilage surface but this does not 
extend to the subchondral bone. Following the injury, nearby cells begin to proliferate, 
cellular attempts to fill the defect cease before it is repaired; full thickness defects arise from 
damage that transverses the entire cartilage thickness and penetrates the subchondral bone. 
In this type cells from bone marrow migrate to fill the defects [30] leading formation of less 
stiff and more permeable tissue than native cartilage, which degrade over a period of months 
[30]; it usually undergoes degeneration within six to twelve months [31]. In the most other 
tissues, such defects would be rapidly repaired without untoward consequences. However, 
adult articular cartilage fails to heal and defects will almost certainly enlarge with time [32]. 
 
Smaller lesion in cartilage can be attempted to be repaired using a variety of methods. 
These methods include implanting replacement tissue grafts, or employing techniques that 
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encourage the native repair process [33]. Autografts are limited by the small amount of 
cartilage available in the body for transplantation to other sites [30;33]. Allografts induce an 
immune response once implanted and perichondrial grafts are reported to have about 70% 
failure at five years [30;33-37]. In cartilage regeneration, many attempts have been made to 
heal or regenerate existing cartilage, rather than replace it. The proposed techniques have 
focused on enhancing the intrinsic regenerative properties of the tissue. Unfortunately, 
neither of these has been completely successful [30;33]. For regeneration enhancement, the 
most common treatment of cartilage degeneration is to penetrate the subchondral bone, 
either by abrasion or drilling. This, in essence, creates a full-thickness defect. A clot forms 
over the bone surface which, can provide a scaffold for migration of MSCs and their 
eventual differentiation into chondrocyte and osteocytes [31]. Also, this technique and other 
regeneration enhancement techniques have some limitations [30;33;34]. However, presently 
these treatments result in limited pain relief and/or restorative tissue function [38-41]. In 
contrast, tissue engineering has the potential to provide a supply of functional cartilage for 
the repair and regeneration of compromised native soft tissues [42]. 
 
There are two major tissue engineering principles employed for cartilage repair. The 
first type is the transplantation of chondrocytes to restore lost tissue mass. An optimal 
approach would be to take a small biopsy of cells, expand the number of cells, and then 
return them to the defect once the proper mass has been generated. This procedure has been 
termed autologous chondrocyte transplantation (ACT) and introduced into clinical therapy. 
However, the success rate has been less than 40%, due to the problem of retaining the cells 
in the defect for a period of time that would allow them to begin to produce matrix [43;44]. 
 
The second tissue engineering principle employs cells in scaffolds. Highly porous 
scaffolds may be used to maintain differentiated cells in a given area. This design is 
favorable because it may significantly reduce donor site morbidity and, in addition to simply 
providing a boundary for retention of cells, the scaffold also acts as a substrate to which the 
anchorage-dependent chondrocytes can adhere [45].  The tissue engineering strategy applied 
in this thesis follows this approach, as illustrated in (Fig. 4). We isolated the chondrocytes 
from bovine knees, and then we dynamically seeded the chondrocytes on polymer scaffolds 
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using bioreactors. For the cell seeding procedure, a cell suspension was prepared and added 
to the bioreactors containing the scaffolds, which were fixed on needles that were pinned to 
the stopper of the spinner flask. Then, the cell suspension was stirred for a period of 48 h to 
achieve homogeneous cell attachment to the scaffolds. Following cell seeding, the cell-
polymer constructs were cultivated in vitro under treatment with different factors in order to 
engineer cartilage-like tissue. The time point of cultivation was varying from 1 week to 4 
weeks. 
 
scaffold cell suspension 
spinner flask Well-plate 
 
Fig. 4. Cartilage tissue culture set-up, including dynamic seeding of chondrocytes on 
scaffolds using spinner flasks and cultivation of cell-polymer constructs in 6-well plates. 
 
 
Factors affecting cartilage tissue engineering 
Cells 
Cells are the most important factor in tissue engineering processes, they are the key to 
generate and repair the tissue due to their proliferation and differentiation capacities, and 
formation of ECM. There are several types of cells that can be used in tissue engineering of 
cartilage. A major sources are primary chondrocytes [46;47] or serially passaged 
chondrocytes in combination with use of differentiation factors [48;49]. Another promising 
Chapter 1     Introduction 
 
 
__________________________________________________________________________________________ 
- 16 - 
possibility is the differentiation of progenitor cells from bone marrow or periosteum called 
mesenchymal stem cells towards the chondrogenic lineage [50]. 
 
Cell carriers (scaffolds)  
A porous cell carrier can provide the necessary support for a developing tissue, 
enabling the 3-D growth. Essential characteristics of scaffolds used for tissue engineering are 
their chemical, physical and biological properties. Scaffolds designed for this purpose should 
ideally provide the following characteristics: (a) a 3-D and highly porous structure to support 
cell attachment, proliferation and ECM production; (b) an interconnected/permeable pore 
network to promote nutrient and waste exchange; (c) a biocompatible and bioresorbable 
substrate with controllable degradation rates; (d) a suitable surface chemistry for cell 
attachment, proliferation and differentiation; (e) mechanical properties to support, or match, 
those of the tissues at the site of implantation; (f) an architecture which promotes formation of 
the native anisotropic tissue structure; and (g) a reproducible architecture of clinically relevant 
size and shape [51-55]. Apart from only being a support for tissue growth, specifically 
tailored biomaterials can also control the adhesion of cells by integrating extracellular matrix 
proteins or their synthetic analogous (RGD sequences) on the scaffold’s surface [56]. During 
cultivation and especially after the transplantation of the scaffold in a defect, it can also be 
used to deliver active growth factors [57]. 
 
The most frequently used biodegradable synthetic polymers have been polyglycolic 
acid (PGA) (Fig. 5A), polylactic acid (PLA), their copolymer of poly (DL-lactic-co-glycolic 
acid) (PLGA), polyvinyl alcohol (PVA) [38;41;58-60] and naturally derived biodegradable 
polymers are collagen (Fig. 5B) [58;61], alginate [62], hyaluronic acid, fibrin glue and 
chitosan [55;58;59;61]. Scaffolds are prepared not only with different materials but also with 
different methods in order to tailor them to a specific applications [51;63-67]. 
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Fig. 5:  SEM image: (A) 3-D PGA scaffold mesh (bar indicates 200 µm); (B) 3-D collagen 
scaffold (bar indicates 1 µm) 
 
Growth factors 
The generation of autologous cartilage implants for clinical use would benefit from 
techniques that (a) decrease the initial number of cells required, thereby minimizing donor site 
morbidity and (b) increase the rate of tissue growth, thereby shortening the in vitro culture 
period. The above improvements can be achieved by the judicious application of growth 
factors, i.e. either, by intermittently supplementing the culture medium with growth factors 
[68;69], by the use of cells genetically engineered to overexpress growth factors [70], or by 
polymeric systems that provide controlled release of growth factors [71;72]. Previous studies 
demonstrated that the exogenous addition of growth factors and some cytokines can be a 
powerful tool to increase the development and stimulate the formation of ECM of the in vitro 
grown tissue [68]. Growth factors can stimulate or inhibit cell division, differentiation and 
migration by binding to their cell specific receptor. They regulate cellular processes such as 
gene expression, DNA and protein synthesis, and autocrine and paracrine factor release. In 
natural cartilage tissue, factors such as IGF-I, TGF-ß and PDGF, are known to stimulate 
chondrocyte proliferation and differentiation and to influence cartilage growth and 
metabolism [73]. Consequently, some of them have been tested recently in tissue engineering 
of cartilage [68;74]. However, investigations of the effects of other potentially very potent 
bioactive protein families or single substances have still to be performed. The increase in 
growth rates of the engineered tissues due to the use of bioactive substances would be a great 
benefit especially for clinical applications. There it is very important to generate constructs of 
A B 
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a given size, or alternatively to produce a larger construct from a given number of harvested 
cells within a given time. 
 
Goals of Thesis 
This thesis focused on the evaluation of the effects of bioactive substances on the quality 
of engineered cartilage in vitro. Also, the potential of novel natural copolymer scaffolds as a 
3-D matrix for chondrocytes were investigated. Additionally, the effects of 3-D long-term in 
vitro culture of chondrocytes were studied. 
 
Bioactive substances  
The first aim was to investigate the effects of the cytokine interleukin-4 and insulin-like 
growth factor binding proteins on the development of tissue engineered cartilage using the 
dynamic cell seeding system. 
 
Interleukin-4 has been previously reported to have stimulatory effects on the development 
of cartilage [68;75] inducing cell proliferation and playing a major role in the maintenance of 
healthy cartilage [75]. Thus it may be a promising candidate for the improvement of 
engineered cartilage (Chapter 3).  
 
Insulin-like growth factor binding proteins (IGFBPs) have the ability to modulate the 
actions of the IGFs, either enhancing or inhibiting them, depending largely on their post-
translational modifications and tissue localization [76;77]. They have been detected in the 
culture media of cultured chondrocytes from various species [78;79]. IGFBP-4 has been 
previously reported to have inhibitory effects on cartilage and bone tissues [80]. The effects 
of IGFBP-4 on engineered cartilage were studied (Chapter 4). IGFBP-5 is expressed by 
chondrocytes and is the predominant IGFBP in bone [81;82], where it can either inhibit or 
increase IGF-I effects [83], in part via an IGF-I-independent mechanism [84]. In the 3-D 
cartilage engineering culture the hypothesis was evaluated that IGFBP-5 may function as a 
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growth factor in cartilage, as it has previously been suggested for bone tissue [85] (Chapter 
5). 
Evaluation of  new natural copolymer scaffolds 
A copolymer scaffold made from hyaluronic acid and gelatin was previously introduced 
for cartilage engineering [86], partially resembling ECM components of native cartilage. As 
these scaffolds initially lacked mechanical stability, they were recently stabilized by chemical 
crosslinking [87]. These newly generated scaffolds were evaluated with regard to their utility 
for cartilage engineering (Chapter 6). 
 
Long-term chondrocyte culture 
We have been monitoring the growth behaviour of long-term 3-D in vitro chondrocyte 
culture for 16 months. The focus was on the cartilage markers GAG and collagen type II, in 
addition the collagen type I and the ossification of the cultivated cartilage was analyzed 
(Chapter 7). 
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Materials: 
Cells 
Knee joints from 2-4 month old bovine calves were obtained from a local slaughter-
house within 6-12 hours of slaughter. The fresh articular cartilage was harvested from the 
surfaces of the femoral patellar groove.  
 
Instruments  
Spinner flasks were self-made (250 ml volume, 6 cm bottom diameter, side arms for 
gas exchange). Silicon stoppers were from Schuber and Weiss (Muenchen, Germany). 
Silicone tubing was from Cole Palmer (Niles, IL). Needles (4 inch long, 22 gauge) were from 
Unimed (Lausanne, Switzerland). Magnetic stirrers were from Bellco (Vineland, NJ). 6-well 
plates were from Corning (Bodenheim, Germany). The Mini orbital shaker SO5 was obtained 
from Stuart Scientific (Surrey, UK). Mastercycler and centrifuge 5415R were obtained from 
Eppendorf AG (Hamburg, Germany). The freeze-drier Christ Beta 2-16 was obtained from, 
Martin Christ Gefriertrocknungsanlagen, GmbH (Osterode am Harz, Germany). The camera 
DSM 950 was from Zeiss (Oberkochen, Germany). The Kodak EDAS 290 was obtained from 
Fisher Scientific (Schwerte, Germany). The microtome CM 1900 was obtained from Leica 
(Nussloch, Germany). The Polaron SC515 was from Fisons surface systems (Grinstead, UK). 
 
Chemicals 
Type II collagenase was from Worthington (Freehold, NJ). Papainase was from 
CellSystem (St. Katharinen, Germany). High glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM), fetal bovine serum (FBS), non-essential amino acids and calcium- and magnesium-
free phosphate buffered saline (PBS) were obtained from Life Technologies GmbH 
(Karlsruhe, Germany). Ascorbic acid, dimethylmethylene blue, diaminobenzidine (DAB), 
eosin, glutaraldehyde, hematoxylin, N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid 
(HEPES buffer), penicillin-streptomycin, proline, glycine, trypan blue, deoxyribonucleic acid 
and safranin-O were purchased from Sigma-Aldrich (Steinheim, Germany). Formalin 37 %, 
chloramin-T and p-dimethylaminobenzaldehyde (p-DAB) were purchased from Merck 
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(Darmstadt, Germany). Hoechst 33258 dye was obtained from Polysciences (Warrington, PA, 
USA). L-hydroxyproline was from Fluka (Neu-Ulm, Germany). Chondroitin sulfate was from 
ICN (Aurora, Ohio, USA). Silver nitrate and OsO4 were obtained from Carl Roth GmbH & 
Co. (Karlsruhe, Germany). Trizol reagent was obtained from Invitrogen GmbH (Karlsruhe, 
Germany). Tissue Tek was obtained from Sakura Finetek (Torrane, CA, USA). Vectastain 
ABC-kit and diaminobenzidine substrate (DAB) and Normal horse serum were obtained from 
Vector Laboratories Inc. (Burlingame, CA, USA). Type II collagen monoclonal antibody 
developed by Rikard Holmdahl/Kristofer Rubin was obtained from the developmental studies 
Hybridoma Bank developed under the auspices of the NICHD and maintained by the 
University of Iowa, Department of Biological Sciences (Iowa City, IA, USA) and Type I 
collagen antibody (monoclonal anti-collagen type I col-1) mouse ascites fluid, was obtained 
from Sigma-Aldrich (Saint Louis, Missouri 63103, USA). 
 
Investigated proteins 
- Interleukin-4 (used in chapter 3) was purchased from R&D Systems (Wiesbaden, 
Germany) 
- Recombinant human IGF-I (used in chapter 3, 4 and 5), recombinant human IGFBP-4 
(used in chapter 4) and recombinant human IGFBP-5 (used in chapter 5) were a gift of 
Roche Pharma Research (Penzberg, Germany) 
- Bovine insulin (used in chapter 6 and 7) from bovine pancreas was obtained from Merck 
(Germany) 
 
Polymer scaffolds 
Polyglycolic acid (PGA) meshes 
These scaffolds were obtained from Albany Int. Research (Mansfield, MA, USA). They 
were produced by forming PGA fibers 12-14 µm in diameter into a 96% porous non-woven 
mesh with a bulk density of 43 mg/cm3. Scaffolds were prepared by die-punching into discs, 
which were 5 mm in diameter and 2 mm thick, sterilized 30 minutes with UV light, and pre-
wetted with 70% ethanol. After rinsing thoroughly with PBS, the scaffolds were kept in 
culture medium and used for in vitro cell culture. 
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Natural copolymer scaffolds 
These copolymer scaffolds were prepared in the Department of Interface Chemistry, 
University of Regensburg, Germany. They were made from three natural biodegradable 
materials (hyaluronic acid, gelatine and collagen type I) and produced by forming sponges 
with pore sizes between 350-450 µm. Scaffolds were prepared by die-punching into discs, 
which were 5 mm in diameter and 2 mm thick, sterilized 30 minutes with UV light, and pre-
wetted with 70% ethanol. After rinsing thoroughly with PBS, the scaffolds were kept in 
culture medium and used for in vitro cell culture. These scaffolds were used only in chapter 6. 
 
Methods 
Chondrocyte isolation  
Chondrocytes were isolated and cultured using sterile technique as follows [88]. The 
cartilage was cut into small cubes, put into centrifuge tubes with 10 ml medium per 1 g tissue. 
The medium contained DMEM with 4.5 g/l glucose, 5% FBS, and 532.5 U/ml of type II 
collagenase. The tubes were placed horizontally on a mini orbital shaker and kept at 50 rpm 
for 16 h at 37 °C in the incubator. The digest was repipetted, filtered through a 150 µm filter 
and centrifuged at 1200 rpm for 5 min. The cell pellet was washed three times with PBS and 
resuspended in culture medium (DMEM containing 0.4 mM proline, 10 mM HEPES buffer, 
0.1 mM non-essential amino acids, 50 U/ml penicillin, 50 µg/ml streptomycin, 50 µg/ml 
ascorbic acid and 10% FBS). The cell number and viability were determined via trypan blue 
exclusion using a hemocytometer and an inverted phase-contrast light microscope. 
The same medium composition used for resuspension of cells was used for cell seeding. The 
same medium was also used for long-term cultivation of cell polymer constructs with the 
exception that the concentration of FBS was reduced to 1% (v/v). 
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In vitro cell culture 
Spinner flasks were used for cell seeding [47]. Scaffolds were threaded onto needles 
(10 cm long, 0.5 mm diameter) and held in place with small segments of silicone tubing (1 
mm long). Four needles with two scaffolds apiece were inserted into a silicone stopper, which 
was in turn placed into the mouth of a spinner flask. The flask was filled with 110 ml culture 
medium and put on a magnetic stir plate at 80 rpm in a humidified 37 °C / 5 % CO2 incubator. 
After 24 h the medium was aspirated and replaced with a cell suspension containing 5 x 106 
chondrocytes per scaffold in 110 ml culture medium. Stirring at 80 rpm in the incubator for 
two days allowed cell attachment to the polymer fibers.  
 
Each cell-polymer construct was then placed in a well of a 6-well plate in 6 ml culture 
medium with 1 % FBS, which was placed on an orbital shaker at 50 rpm. After two days the 
culture medium was changed and from this time point the proteins (IL-4, insulin, IGF-I, 
IGFBP-4, or IGFBP-5) were added with each medium exchange three times per week for up 
to four weeks. IL-4 was added at concentrations of 1 and 10 ng/ml, IGF-I at 5 and 50ng/ml, 
and insulin at 2.5 µg/ml for 4 weeks in chapter 6 and for 16 months in chapter 7. IGFBP-4 
was added at concentrations of 15.8, 157.9, 474, 1579 and 15790 ng/ml or in combinations 
with IGF-I in the following molar ratios 1:0.5, 1:1, 1:3, 1:10 and 1:100 (IGF-I (50 
ng/ml):IGFBP-4) in chapter 4. IGFBP-5 was added at concentrations of 9.5, 95, 572 and 1909 
ng/ml or in combination with IGF-I in the following ratios 1:0.5, 1:1, 1:3, and 1:10 (IGF-I (50 
ng/ml):IGFBP-5) in chapter 5. Three constructs were cultured per group  
 
Analysis of engineered tissues 
Biochemical analysis 
 
Cell-polymer constructs were analyzed as previously described [68;89]. The constructs 
were weighed (= wet weight) and cut in half. One part of the construct was lyophilized, then 
digested with a papainase solution (3.2 U/ml in buffer) and used for the determination of cell 
number, collagen content, and glycosaminoglycan content. The number of chondrocytes was 
determined fluorometrically by measuring the amount of DNA using Hoechst 33258 dye [90]. 
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The total collagen content was determined spectrophotometrically with p-
dimethylaminobenzaldehyde and hydroxyproline [91] and calculated using a hydroxyproline 
to collagen ratio of 1:10 [92]. The amount of sulfated glycosaminoglycans was determined 
spectrophotometrically at 525 nm as chondroitin sulfate using dimethylmethylene blue [93].  
 
Histology 
A part from the cell-polymer construct was prepared as a histological sample by fixing 
in 2% glutaraldehyde for 30 min and then storing in 10% formalin. After that, the samples 
were embedded in paraffin and cut into 5 µm sections; deparaffinized sections were stained 
with safranin-O for the detection of GAG.  
 
Immunohistology  
A part from the cell-polymer constructs were prepared for immunohistochemical 
staining by fixing in methanol-formalin mixture, then successively incubated in different 
concentrations (5% - 40%) of a sucrose solution followed by Tissue-Tek. Frozen samples 
were cryosectioned at 10 µm and stained with antibodies for type I collagen (monoclonal anti-
collagen type I col-1) mouse ascites fluid, dilution (1: 2000) and type II collagen (DSHB), 
dilution (1: 6). The samples were dehydrated in PBS containing 0.1% Tween-80, antigen 
retrieval was performed by pepsin digestion. To prevent non-specific antibody binding, 
sections were incubated with 5% normal horse serum in PBS. The sections were then 
incubated overnight at room temperature with the primary antibodies; for control sections, 
PBS was used instead of the primary antibody.  Further incubation with a biotinylated 
secondary antibody, anti-mouse/rabbit IgG (Vector Laboratories; Inc.; Burlingame, CA, 
USA), was performed for 30 min at room temperature after washing with PBS. The sections 
were then stained using a Vectastain ABC-kit and diaminobenzidine substrate (DAB) (Vector 
Laboratories Inc.; Burlingame, CA, USA) for avidin-biotin-peroxidase complexes formation.  
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Reverse transcription polymerase chain reaction (RT-PCR): 
Total RNA was harvested from the cells (constructs) with the Trizol reagent and 
isolated according to manufacturer’s instructions. First-strand cDNA was synthesized from 
total RNA by using Oligo (dT)12-18 primer (Invitrogen; Karlsruhe, Germany) and Superscript 
II RNase H- Reverse Transcriptase (Invitrogen GmbH; Karlsruhe, Germany). Samples were 
incubated at 42°C for 50 min and heated afterwards for 15 min at 70°C to inactivate the 
enzyme. Subsequently, PCR was performed with Sawady Taq-DNAPolymerase (PeqLab, 
Erlangen, Germany); initial denaturation occurred at 94°C for 120 sec, final extension at 72°C 
for 30 sec, and holding at 4°C. The amplification was carried out using specific primers and 
appropriate conditions for each gene (Tab. 1), primers were purchased from MWG-Biotec AG 
(Ebersberg, Germany). GAPDH served as control. Reverse transcription and PCR were 
performed using a Mastercycler.  
The PCR products were analyzed by electrophoresis in 2% agarose gels stained with 
ethidium bromide. Finally, the gels were subjected to imaging and densitometric scanning of 
the resulting bands under UV light (λ = 312 nm) using a Kodak EDAS 290. 
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Table 1: Primer sequences and PCR conditions for the investigated genes  
Oligonucleotide sequences of forward (sense) and reverse (antisense) primers. Gene 
amplification was performed by PCR according to the specified annealing temperatures (AT) 
and number of cycles for each gene. The reaction conditions of one cycle were as follows: 
denaturation for 45 sec at 94°C, annealing for 45 sec at the indicated temperatures, and 
extension for 1 min at 72°C. Table 1: Primer sequences and PCR conditions for the 
investigated genes. 
Gene Forward and reverse primers of examined genes AT (°C) / Cycles 
Aggrecan 5‘-CAC TGT TAC CGC CAC TTC CC-3‘ (S) 
5‘-GAC ATC GTT CCA CTC GCC CT-3‘ (AS) 
53/36 
 
Biglycan 5‘-AAC ATG AAC TGC ATT GAG AT-3‘ (S) 
5‘-ACT TGG AGT AGC GGA CGA GA-3‘ (AS) 
47/36 
 
MMP-1 5’-AGGTTATCCCAAAATGATAG-3’ (S) 
5’-TGCAGTTGAACCAGCTATTA-3’ (AS) 
47/36 
 
MMP-3 5’-CTTTTGGCGMAAATCYCTCAG-3’ (S) 
5’-AAARRAACCCAAATKCTTCAA-3’(AS) 
47/36 
 
MMP-13 5’-T(GT)C GGT C(AT)C A (CT)G CTT TTC CTC-3’ (S) 
5’-GGT TGG GGT CTT CAT CTC CTG-3’ (AS) 
54/36 
 
TIMP-1 5’-CCA CCT TAT ACC AGC GTT AT-3’ (S) 
5’- CCT CAC AGC CAA CAG TGT AGG-3’ (AS) 
50/36 
GAPDH 5‘-TGG TAT CGT GGA AGG ACT CAT-3‘ (S) 
5‘-GTG GGT GTC GCT GTT GAA GTC -3‘ (AS) 
53/36 
 
 
 
Scanning electron microscopy  
A part from cell-polymer constructs were rinsed three times with PBS. Afterwards, it 
was fixed with glutaraldehyde (2.5% in PBS) for 15 min. Cells were further fixed with an 
aqueous solution of osmium tetroxide (OsO4) (1%) on ice for 30 min. The excess OsO4 was 
removed with several washes with water. Then, the samples were frozen at -80 °C and freeze-
dried.  For scanning electron microscopy, sample were mounted on aluminium stubs using 
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conductive carbon tape and coated with gold-palladium (Polaron SC515). Photomicrographs 
were acquired at 10 kV on a DSM 950. 
 
Von Kossa stain 
Matrix mineralization of the cell-polymer constructs of the long term experiment 
(Chapter 7) was assessed by von Kossa silver nitrate staining. Samples were harvested after 1, 
4, 8, 12, and 16 months of dynamic cultivation and fixed and cryosectioned as described in 
immunohistology. Then the sections were fixed with 10% formalin in PBS for 12 h. They 
were washed thoroughly with water to remove residuals of PBS, incubated in 5% aqueous 
silver nitrate solution, and exposed to natural light for 30 min. Then the sections were washed 
with water to remove excess of von Kossa silver nitrate staining. After that, they were 
counter-stained with safranin-O.  
 
Statistical analysis 
Statistical significance (* = p<0.05; ** = p<0.01 compared to control groups; + = 
p<0.05; ++  = p<0.01 between two groups) was assessed by one-way analysis of variance 
(ANOVA) in conjunction with Tukey’s studentized range test, or a two-tailed unpaired 
Student’s t test. 
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Effects of Interleukin-4 on Extracellular Matrix Content 
and Matrix Metalloproteinase Expression in Engineered 
Cartilage 
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Introduction 
Three-dimensional chondrocyte cultures can be used to investigate the usefulness of 
growth factors and cytokines for cartilage engineering purposes [68;94;95]. This study was 
performed in order to evaluate the potential of IL-4 to improve the quality of tissue-
engineered cartilage.  
 
IL-4, a 20 kD glycoprotein, is a B cell growth and differentiation factor [96;97] 
secreted by activated T lymphocytes. The ability of IL-4 to suppress the synthesis of the 
catabolic factors interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α) and the 
arachidonic acid metabolite prostaglandin E2 in human monocytes has been reported [98]. 
The effect of IL-4 as an inhibitor for bone resorption has been demonstrated [99]. In human 
alveolar macrophages, IL-4 suppresses the biosynthesis of both interstitial collagenase and 92 
kDa gelatinase [100]. IL-4 can exert its effect through an increase in mRNA levels of the IL-1 
type 1 receptor (IL-1RI), a soluble receptor for neutralizing IL-1 activity in 
polymorphonuclear cells, and by inducing the expression and release of IL-1RII, a decoy 
target for IL-1 [101;102].  
 
In cartilage explants, IL-4 has been shown to inhibit the degradation of proteoglycans, 
a major component of cartilage ECM [75], though the mechanisms of action are still 
controversially discussed [75;103-106]. Yeh et al. [75] found that IL-4 had no effect on 
TIMP-1 levels in bovine articular cartilage conditioned media by Western blot analysis, while 
Nemoto et al. [104] found that IL-4 suppresses MMP-3 synthesis in human articular 
chondrocytes. In contrast, Shingu et al. [103] reported the effects of IL-4 on rheumatoid 
arthritis chondrocytes in culture and found that IL-4 enhanced TIMP-1 production without 
affecting MMP-3. Cawston et al. [107] reported that IL-4 increased TIMP-1 secretion and 
reduced the secretion and activation of MMP-1 by bovine nasal cartilage. 
 
In this study, the effect of IL-4 on tissue engineered cartilage was studied with a focus on the 
ECM content. A clearly defined 3-D culture system was employed in order to contribute to 
the elucidation of mechanisms of IL-4 action modulating ECM composition. RT-PCR was 
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utilized to evaluate the contributions of increased synthesis of various GAG subtypes and 
inhibition of GAG degradation. The effects of IL-4 were compared to those of IGF-I, which 
has potent stimulatory effects on chondrocyte proliferation and ECM synthesis and has 
previously been successfully employed to improve the growth rate of the cells and ECM 
composition in tissue engineered cartilage [68;94]. 
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Results 
Weights of engineered tissues 
Wet weights of cell-polymer constructs cultured in medium supplemented with IL-4 (1 
and 10 ng/ml) were not affected during the first two weeks of culture, as compared to control 
constructs. However, IL-4 dose dependently increased the wet weights of the constructs after 
four weeks of cultivation (1.7-fold increase for 10 ng/ml IL-4, compared to control). The 
constructs supplemented with IGF-I (50 ng/ml) showed significant increases in the wet 
weights over the whole course of four weeks culture compared to controls (2.8 -fold increase 
after 4 weeks of culture, compared to control) (Fig. 6). 
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Fig. 6: Effects of IL-4 (1 and 10 ng/ml) and IGF-I (50 ng/ml) on the wet weight of cell-
polymer constructs cultured for four weeks. Data represent the average ± SD of three 
constructs. Significance to the control is indicated by *, significance between two groups is 
indicated by +. 
 
 
 
Cell number 
The cell number per wet weight of the constructs supplemented with IL-4 (1 and 10 
ng/ml) was not affected after one week; however, it was significantly decreased after two and 
four weeks, as compared to control constructs receiving no additional proteins. The addition 
of IGF-I (50 ng/ml) significantly decreased the cell number per wet weight of the constructs 
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throughout the whole culture period, as compared to control constructs (Fig. 7). A lower cell 
number within the engineered tissues is desirable in order to approach a native-like tissue 
quality. 
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Fig. 7: Effects of IL-4 (1 and 10 ng/ml) and IGF-I (50 ng/ml) on the cell numbers per wet 
weight of cell-polymer constructs cultured for four weeks. Data represent the average ± SD of 
three constructs. Significance to the control is indicated by *, significance between two 
groups is indicated by +. 
 
ECM quantification 
The amount of GAG per wet weight was significantly increased in the constructs 
treated either with IL-4 (1 and 10 ng/ml) or IGF-I (50 ng/ml) after one and four weeks (1.4-
fold increases after four weeks compared to control). (Fig. 8). The total amount of collagen 
per wet weight of the constructs was significantly increased with the addition of IL-4 (1 
ng/ml) after one and two weeks; the effects were not significant after 4 weeks. In contrast, IL-
4 at 10 ng/ml significantly increased the amount of collagen per ww of the constructs after 
two and four weeks, as compared to control. The addition of IGF-I (50 ng/ml) to the culture 
medium significantly increased the amount of collagen per wet weight in the constructs after 
one and two weeks, while after four weeks the effect of IGF-I was not significant, as 
compared to controls (Fig. 9). 
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Fig. 8: Effects of IL-4 (1 and 10 ng/ml) and IGF-I (50 ng/ml) on the GAG per wet weight of 
cell-polymer constructs cultured for four weeks. Data represent the average ± SD of three 
constructs. Significance to the control is indicated by *, significance between two groups is 
indicated by +. 
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Fig. 9: Effects IL-4 (1 and 10 ng/ml) and IGF-I (50 ng/ml) on the collagen per wet weight of 
cell-constructs cultured for four weeks. Three independent long-term cell culture experiments 
were performed; result from a representative experiment was shown here. Data represent the 
average ± SD of three. Significance to the control is indicated by *, significance between two 
groups is indicated by +. 
 
 
In another experiment combinations of IL-4 and IGF-I (1:50 and 10:50 ng/ml) were 
added into the culture medium of the constructs over four weeks of cultivation. The wet 
weight of the constructs as well as the amounts of GAG and collagen per ww were increased, 
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as compared to the controls and compared to either IGF-I or IL-4 alone. Also, these 
combinations decreased the cell number per ww of the constructs (data not shown).  
 
Histology 
Safranin-O staining confirmed the results from GAG quantification: Compared to 
control constructs, the GAG content was considerably higher in constructs supplemented with 
either IL-4 or IGF-I after 4 weeks. However, only constructs receiving IL-4 exhibited a 
homogeneous GAG distribution throughout the whole cross-section, i.e., also at the edges of 
the construct (Fig. 10). In IGF-I supplemented cell-polymer constructs there was a zone at the 
edges of the sections depleted of GAG, this zone stained green and appeared slightly lights in 
the black and white print. 
 
Collagen type II, a marker for differentiated chondrocytes was detected 
immunohistologically at high levels and homogenously distributed in the constructs 
supplemented with IL-4 (1 and 10 ng/ml) as well as in the constructs supplemented with IGF-
I and in control constructs (Fig. 11).  
 
Collagen type I was detected at the surfaces of the control and IGF-I supplemented 
constructs corresponding to the zones that contained flat, elongated, fibroblast-like cells. This 
zone almost disappeared in the constructs supplemented with IL-4 (1 ng/ml) and appeared 
very thin in the constructs supplemented with IL-4 (10 ng/ml) (Fig. 11). 
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Fig. 10: Histological cross-sections of one, two and four week constructs grown in culture 
medium with 1% FBS: GAG in ECM was stained red with safranin-O (dark color in the 
black and white print) (x 100). Three independent long-term cell culture experiments were 
performed; result from a representative experiment was shown here. 
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Fig. 11: Immunohistological cross-sections of four week constructs grown in culture medium 
with 1% FBS: collagen type I and II were stained black with collagen type I and II antibodies 
(x 100). Immunohistological staining was performed after two independent long-term cell 
culture experiments; result from a representative experiment was shown here. 
 
 
Examination of mRNA gene expression  
 
In order to gain further insight into how IL-4 increases the GAG content in the 
cultivated constructs, investigations into mRNA gene expression were performed by means of 
RT-PCR at days 0, 7, 14 and 28 of cultivation. We focused on analysis of the GAG subtypes 
aggrecan and biglycan, the degradatory enzymes matrix metalloproteinases MMP-1, -3 and -
13, and the tissue inhibitor of metalloproteinase TIMP-1.  
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Examination of the expression of the GAG subtypes aggrecan and biglycan revealed 
that all band intensities were not affected by the addition of IL-4 to the construct cultures 
during the whole period of cultivation compared to controls. Also, the addition of IL-4 to the 
construct had no effect on any of the band intensities of TIMP-1. The addition of IL-4 to the 
culture medium had no effect on the band intensities of MMP-1 and only slightly increased 
the expression of MMP-3. However, the addition of IL-4 into the culture medium strongly 
inhibited the expression of MMP-13. The effect of IL-4 on MMP-13 expression was increased 
with time of exposure to IL-4, i.e., there were moderate effects after one and two weeks, but 
after four weeks the expression of MMP-13 was strongly inhibited compared to controls and 
also compared to constructs receiving IGF-I (Fig. 12) 
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Fig. 12: Evaluation of differential gene expression in engineered cartilage at days 0, 7, 14 and 
28 of cultivation in medium containing 1% FBS with and without IGF-I and IL-4 by means of 
RT-PCR. MMP-1, -3 and -13, TIMP-1, aggrecan, biglycan and GAPDH were investigated. 
Three independent long-term cell culture experiments were performed; results from a 
representative experiment were shown here. 
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Discussion 
This study was designed to evaluate the usefulness of IL-4 for tissue-engineered 
cartilage grown in a well-established in vitro model system, focusing on its ability to increase 
the amount of ECM, especially the amount of GAG. The effects of IL-4 were compared to 
those of IGF-I, which has been shown to have potent stimulatory effects on chondrocyte 
proliferation and ECM synthesis [68;94]. 
 
In this study IL-4 (1 and 10 ng/ml) increased the weight of constructs and increased 
the formation of extracellular matrix, particularly GAG content after long-term treatment (4 
weeks). IL-4 also affected the GAG distribution in the constructs: In IL-4 supplemented 
constructs GAG was distributed throughout the whole cross-section of the construct, whereas 
both control and IGF-I supplemented groups lacked GAG at the edge of the constructs. 
 
IL-4 has been reported to affect GAG content in cartilage in previous studies, 
however, as of yet the precise mechanism of action of IL-4 on GAG is not fully understood. 
IL-4 has been shown to have the ability to inhibit the proteoglycan degradation in cartilage 
[75]. IL-4 appeared to either suppress MMP-3 synthesis [104] or downregulate other cartilage 
degradatory systems, but without affecting TIMP-1 levels [75]. In contrast, Shingu et al. [103] 
investigated the effects of IL-4 using rheumatoid arthritis (RA) chondrocytes in culture and 
found that IL-4 enhanced TIMP-1 production without affecting MMP-3. The contrasting 
reports may be explained on the basis of differential species or disease responsiveness. As a 
further potential mechanism it has been reported that IL-4 interferes with IL-1 or TNF-alpha, 
inhibitors of proteoglycan synthesis [108]. IL-4 can potentially shift the balance between 
GAG synthesis and degradation. In many cell types IL-4 was shown to diminish IL-1 gene 
expression and/or to promote the expression of the IL-1 receptor antagonist protein that 
blocks the action of IL-1 [105;106;109]. Suppression of IL-1 synthesis may lead in turn to 
blocking of the IL-1 stimulated MMP-3 production. Furthermore, the potent anti-
inflammatory properties of IL-4 in various cell types indicate that IL-4 has a protective role in 
the catabolic pathway of osteoarthritis (OA) [110;111].  
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RT-PCR was used to contribute to the elucidation of the mechanisms by which IL-4 
increased the GAG content in the cultivated cell-polymer constructs. The mechanisms of 
enhancing effects of IL-4 on the ECM formation might include one of the following: 1) 
inhibiting the release of the matrix metalloproteinases (MMP-1, MMP-3 and MMP-13); 2) 
increasing the release of the tissue inhibitor matrix metalloproteinase (TIMP-1); and 3) 
increasing GAG subtype synthesis (aggrecan and biglycan). Whereas effects of IL-4 on 
MMP-1, MMP-3, and TIMP-1 expression have been suggested previously, this study was the 
first to investigate the effects of IL-4 on MMP-13 expression. The results of this study 
indicated that IL-4 had distinct inhibitory effects on MMP-13 gene expression without 
significantly affecting the other factors. These inhibitory effects on MMP-13 expression 
increased with time of IL-4 treatment; the most dramatic effects were observed at late stages 
of the culture, corresponding well with the late increase of GAG content provoked by IL-4. 
 
MMP-13 has been shown to degrade collagen type I, II and III, preferably type II, 
which is the primary collagen found in articular cartilage [112]. The primary role of MMPs , 
particularly MMP-1 and MMP-13, in the specific cleavage of the triple helix of type II 
collagen in arthritis is well-established [113;114]. MMP-13 also degrades the cartilage 
proteoglycan aggrecan. It cleaves aggrecan at three sites, that is, in the interglobular domain 
(IGD) at the same site identified for other members of the MMP family, and also at another 
site not observed for other MMPs [115]. Little et al. [116] reported that MMPs were 
responsible for C-terminal catabolism of aggrecan and the generation of chondroitin sulfate 
(CS). Recombinant MMP-1, -3 and –13 were all capable of C-terminally truncating aggrecan 
with at least two cleavage sites on the N-terminal side of the CS attachment domains of 
aggrecan. All three MMPs resulted in a very similar pattern of metabolites, suggesting that 
they cleave similar sites within the aggrecan C-terminus, although MMP-1 appeared to be the 
most efficient at generating the 75 kDa metabolite. Digestion with MMP-13 for 16 h resulted 
in an intermediate band of approximately 100 kDa, suggestive of an additional C-terminal 
cleavage site by this enzyme when compared with the two other MMPs tested. It has been 
reported that MMPs also have cleavage sites within the CS attachment regions of aggrecan as 
well as the IGD [117;118].  
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Summary  
The study was designed to evaluate the effects of interleukin-4 (IL-4) on tissue 
engineered cartilage focusing on its ability to modulate the extracellular matrix (ECM) 
content. Bovine articular chondrocytes were seeded on polyglycolic acid scaffolds in spinner 
flask for two days, after which cell-polymer constructs were transferred into 6-well plates. 
Constructs were cultured for up to four weeks in medium containing 1% FBS either with or 
without supplemented proteins.  
 
IL-4 exhibited profound stimulatory effects on engineered cartilage. It increased the 
wet weight of the cell-polymer constructs and decreased the cell number per wet weight. As 
detected by biochemical analysis and histological staining, IL-4 significantly increased the 
fractions of glycosaminoglycans (GAG) per wet weight and improved the GAG distribution 
minimizing GAG depleted areas at the construct edges which were observed in control 
constructs. 
 
The mechanism by which IL-4 increases the GAG content might be either inhibition 
of GAG degradation or increased GAG subtype synthesis. In order to elucidate the respective 
contributions, RT-PCR was employed to investigate the expression of (1) matrix 
metalloproteinases MMP-1, MMP-3, MMP-13; (2) tissue inhibitor of metalloproteinases-1 
(TIMP-1); and (3) GAG subtypes aggrecan and biglycan. IL-4 was demonstrated to have 
distinct inhibitory effects on MMP-13 expression without significantly affecting any of the 
other factors investigated. Our results suggest that IL-4 increases the GAG fractions in 
engineered cartilage at least in part by decreasing the MMP-13 expression and thus inhibiting 
GAG degradation. 
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Introduction 
IGFBPs are a family of six or more related proteins with a high affinity for IGF-I 
[119-121]. This group of proteins have the ability to modulate the actions of the IGFs, either 
enhancing or inhibiting them, depending largely on their post-translational modifications and 
tissue localization [76;77]. IGFBPs-1 to -6 have been isolated and their cDNAs have been 
cloned [122]. They have been detected in culture media of cultured articular chondrocytes 
[78;79;81;123] and in intact bovine cartilage [124]. The predominant IGFBPs produced by rat 
articular chondrocytes were IGFBP-3, -4 and -5 [125]. An increase in IGFBP mRNAs in 
osteoarthritic chondrocytes and in the culture medium of osteoarthritic cartilage slices and in 
monolayer culture has been observed [126-128]. In osteoarthritic cartilage, the normal 
anabolic function of IGF-I may be disrupted. Chondrocytes from animals with experimental 
arthritis and from patients with osteoarthritis are non-responsive to IGF-I, although they 
express increased levels of IGF-I and the IGF-I receptor [128;129]. These findings may be 
explained by the hypothesis that the IGFBPs play an inhibitory role during the disease, 
blocking the actions of IGF-I [126-128].  
 
IGFBP-4 has been proposed to play an important role in the regulation of cartilage and 
bone formations. It has been shown to inhibit the growth of embryonic chick pelvic cartilage 
in vitro [80]. It is a potent inhibitor of IGF-induced cell proliferation in a number of cell types 
in vitro [130]. In vitro studies on the mechanism by which IGFBP-4 inhibits osteoblast cell 
proliferation show that IGFBP-4 may inhibit IGF actions in osteoblasts by preventing the 
binding of IGF ligand to its membrane receptors [130;131].  
In this study, the hypothesis that IGFBP-4 inhibits the growth of cartilage in absence 
of IGF-I was evaluated in a well-established 3-D culture system. In addition, the inhibitory 
effects of IGFBP-4 on the actions of IGF-I, which has potent stimulatory effects on 
chondrocyte proliferation and extracellular matrix synthesis [68], were investigated. 
Specifically, we investigated if exogenous IGFBP-4 was able to inhibit the growth rate and 
compromise the concentrations of ECM components of cell-polymer constructs. Also, the 
effects of IGFBP-4 in combination with IGF-I on in vitro engineered cartilage were studied in 
the same model. 
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Results 
Wet weight 
The addition of IGF-I (5 and 50 ng/ml) to the culture medium increased the construct 
wet weights by up to 1.8-fold for 50 ng/ml, compared to control values, over 4 weeks of 
cultivation (Fig. 13A and Table 2). The addition of IGFBP-4 (15.8–15790 ng/ml) to the 
culture medium significantly decreased construct wet weights in a dose-independent manner 
to as low as 15 % of control values over 4 weeks of cultivation. In detail, IGFBP-4 at 15.8 
ng/ml did not change the construct wet weight significantly, while at higher concentrations of 
158, 474, 1579, and 15790 ng/ml, it significantly decreased the construct wet weights to 78, 
56, 29 and 15% of control values, respectively (Fig. 13A and Table 2).  
The combination of IGF-I (50 ng/ml) and IGFBP-4 in different molar ratios (MRs) 
decreased construct wet weights over 4 weeks of cultivation, as compared to IGF-I alone. In 
detail, 1:0.5, 1:1 and 1:3 MRs decreased the weights to 54-62%, whereas at 1:10 and 1:100 
the weights were decreased to 42% and 12% of IGF-I values (Fig. 13B).  
(Please note: The molecular weight of IGFBP-4 is 24 kDa, that of IGF-I is 7.6 kDa. 
Therefore, in order to employ molar ratios of 1:0.5, 1:1, 1:3, 1:10 and 1:100, IGFBP-4 
concentrations of 78.9, 157.9, 474, 1579 and 15790 ng/ml had to be used in combination with 
50 ng/ml of IGF-I (Fig. 13B). Based on these concentrations, the concentrations for the 
experiments employing IGFBP-4 alone were chosen (Fig. 13A)). 
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Fig. 13A: Effects of IGFBP-4 (15.8-15790 
ng/ml) and IGF-I on the wet weight of 
constructs cultured for four weeks. Data 
represent the average ± SD of three 
independent measurements. Significance to 
the control is indicated by *, Significance 
between two groups is indicated by +. 
Fig. 13B: Effects of IGF-I (50 ng/ml) and 
IGF-I: IGFBP-4 in different molar ratios 
on the wet weight of constructs cultured for 
four weeks. Data represent the average ± 
SD of three independent measurements. 
Significance to the control is indicated by *, 
significance between two groups is 
indicated by +. 
 
Cell number 
The addition of IGF-I at 5 and 50 ng/ml to the culture medium of the cell-polymer 
constructs decreased the cell number per wet weight of the constructs (to 72% for 50 ng/ml of 
control values) (Fig. 14A and Table 2). Addition of IGFBP-4 (15.8–15790 ng/ml) to the 
culture medium of the cell-polymer constructs increased the cell number per wet weight in a 
dose-independent manner (up to 3.9-fold increase for 15790 ng/ml compared to control 
values) (Fig. 14A and Table 2).  
The combination of IGF-I (50 ng/ml) and IGFBP-4 in different MR significantly 
increased the cell number per construct wet weight as compared to IGF-I alone, that is, MR of 
1:0.5 to 1:10 led to 1.5-fold to 2.1-fold increases, whereas a MR of 1:100 increased the cell 
number per weight 4.5-fold, as compared to IGF-I (Fig. 14B). 
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Fig. 14A: Effects of IGFBP-4 (15.8-15790 
ng/ml) and IGF-I on the cell number per wet 
weight of constructs cultured for four weeks. 
Data represent the average ± SD of three 
independent measurements. Significance to 
the control is indicated by *, significance 
between two groups is indicated by +. 
Fig. 14B: Effects of IGF-I (50 ng/ml) and 
IGF-I: IGFBP-4 in different molar ratios on 
the cell number per wet weight of constructs 
cultured for four weeks. Data represent the 
average ± SD of three independent 
measurements. Significance to the control is 
indicated by *, significance between two 
groups is indicated by +. 
 
 
Major ECM components 
Collagen fractions 
IGF-I (50 ng/ml) increased the amount of total collagen in the cell-polymer constructs 
3.5-fold, as compared to controls; the fraction of collagen per wet weight was increased 1.9-
fold. The addition of IGFBP-4 (15.8–15790 ng/ml) to the culture medium of the cell-polymer 
constructs decreased the amount of collagen in a dose-dependent manner. In detail, IGFPB-4 
at 15.8 ng/ml did not affect the amount of collagen per construct, and at higher concentrations 
of 158, 474, 1579, and 15790 ng/ml, IGFBP-4 decreased the amount of collagen per construct 
to 84, 57, 28 and 11% of the control values, respectively. The fraction of collagen per wet 
weight was only significantly changed at 15790 ng/ml (decrease to 73%) (Fig. 15A and Table 
2). 
The combination of IGF-I (50 ng/ml) and IGFBP-4 drastically decreased collagen 
amounts per construct. In detail, at 1:0.5, 1:1 and 1:3 molar ratios, collagen amounts where 
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reduced to 38-39%, whereas at 1:10 and 1:100, collagen amounts were reduced to 23% and 
5.2%, respectively, as compared to IGF-I alone. The collagen fraction per wet weight was 
also reduced at all molar ratios, as compared to IGF-I alone (44% at 1:100) (Fig. 15B and 
Table 3). 
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Fig. 15A: Effects of IGFBP-4 (15.8-15790 
ng/ml) and IGF-I on the amount of total 
collagen per construct cultured for four weeks. 
Data represent the average ± SD of three 
independent measurements. Significance to the 
control is indicated by *, significance between 
two groups is indicated by +. 
Fig. 15B: Effects of IGF-I (50 ng/ml) and 
IGF-I: IGFBP-4 in different molar ratios on 
the amount of total collagen per construct 
cultured for four weeks. Data represent the 
average ± SD of three independent 
measurements. Significance to the control is 
indicated by *, significance between two 
groups is indicated by +. 
 
GAG fractions 
IGF-I at 50 ng/ml increased the amount of GAG per cell-polymer construct 3-fold and 
the fraction of GAG per wet weight 1.6-fold, as compared to control constructs. The addition 
of IGFBP-4 (15.8–15790 ng/ml) to the culture medium dose-dependently decreased the 
amounts of GAG per construct. In detail, IGFBP-4 at 15.8 and 158 ng/ml did not significantly 
affect the amount of GAG, while at higher concentrations (474, 1579, and 15790 ng/ml) it 
significantly decreased the amount of GAG per construct to 72, 38, and 13% of control 
values, respectively. The GAG fraction per wet weight was significantly decreased (to 72%) 
only at a concentration of 15790 ng/ml (Fig. 16A and Table 2).  
The combination of IGF-I (50 ng/ml) and IGFBP-4 drastically decreased the amounts 
of GAG per construct, as compared to IGF-I alone. Whereas molar ratios of 1:0.5 to 1:3 
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resulted in decreases to 43-46%, at molar ratios of 1:10 and 1:100, GAG per construct was 
reduced to 24% and 6.1%, respectively, of IGF-I values. The GAG fraction per wet weight 
was also reduced at all molar ratios, as compared to IGF-I alone (47% at 1:100) (Fig. 16B and 
Table 3). 
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Fig. 16A: Effects of IGFBP-4 (15.8-15790 
ng/ml) and IGF-I on the amount of 
glycosaminoglycan per construct cultured for 
four weeks. Data represent the average ± SD of 
three independent measurements. Significance 
to the control is indicated by *, significance 
between two groups is indicated by +. 
Fig. 16B: Effects of IGF-I (50 ng/ml) and 
IGF-I: IGFBP-4 in different molar ratios 
on the amount of glycosaminoglycan per 
construct cultured for four weeks. Data 
represent the average ± SD of three 
independent measurements. Significance 
to the control is indicated by *, 
significance between two groups is 
indicated by +. 
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Table 2: Comparison of four week cell-polymer constructs cultured without or with 
supplemental IGF-I (5 and 50 ng/ml) or supplemental IGFBP-4 (15.8-15790 ng/ml). 
conc. ww cell number 
per ww 
collagen/ww collagen/ 
construct 
GAG/ww GAG/ 
construct 
ng/ml mg 1/µg % mg % mg 
control 0 85 ± 9.8 91 ± 12 2.6 ± 0.06 2.2 ±  0.02 2.2 ± 0.23 1.8 ± 0.09 
5 117± 16 82 ± 4 4.7± 0.37 5.6 ± 0.35  3.7 ± 0.48 4.3 ± 0.86 IGF-I 
50 153 ± 5 66 ± 6.8 5.0 ± 0.08 7.66 ± 0.24 3.6 ± 0.05 5.4 ± 0.27 
15.8 80 ± 2 130 ± 11 2.8 ± .04 2.22 ± 0.09 2.3 ± 0.29 1.8 ± 0.19 
158 67 ± 7 142 ± 16 2.8 ± 0.22 1.86 ± 0.04 2.6 ± 0.15 1.7 ± 0.28 
474 47 ± 4.4 150 ± 6 2.7 ± 0.38 1.26 ± 0.16 2.7 ± 0.13 1.3 ± 0.08 
1579 25 ± 2 230 ± 0.2 2.5 ± 0.28 0.63 ± 0.04 2.8 ± 0.21 0.7 ± 0.04 
IGFBP-4 
15790 13 ± 2 353 ± 61 1.9 ± 0.21 0.25 ± 0.06 1.7 ± 0.34 0.23 ± 0.04 
 
Table 3: Comparison of four week cell-polymer constructs cultured without or with 
supplemental IGF-I (50 ng/ml) or supplemental IGF-I (50 ng/ml): IGFBP-4 (1:0.5, 1:1, 1:3, 
1:10 and 1:100 molar ratio). 
conc. ww cell number 
per ww 
collagen/ww collagen/ 
construct 
GAG/ww GAG/ 
construct 
 
ng/ml mg 1/µg % mg % mg 
control 0 85 ± 9.8 91 ± 12 2.6 ± 0.06 2.2 ±  0.02 2.2 ± 0.23 1.8 ± 0.09 
IGF-I 50 153 ± 5 66 ± 6.8 5.0 ± 0.08 7.7 ± 0.24 3.6 ± 0.05 5.4 ± 0.27 
1:0.5 82 ± 28 126 ±  18 3.53 ± 0.16 2.9 ± 0.82 2.8 ± 0.7 2.3 ± 0.48 
1:1 93 ± 10 108 ± 2.1 3.3 ± 0.06 3.0 ± 0.3 2.6 ± 0.18 2.5 ± 0.11 
IGF-I: 
IGFBP-4 
1:3 95 ± 7 99 ± 3.2 3.1 ± 0.27 2.9 ± 0.4 2.5 ± 0.17 2.4 ± 0.12 
1:10 64 ± 14 140 ± 12.3 2.8 ± 0.35 1.8 ± 0.5 2.0 ± 0.2 1.3 ± 0.12  
1:100 19 ± 1.7 299 ± 20 2.2 ± 0.2 0.4 ± 0.01 1.7 ± 0.09 0.33 ± 0.04 
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Histology 
 
Constructs grown under control conditions and in IGF-I–supplemented medium 
appeared histologically cartilaginous with round chondrocytes in lacunae and an ECM that 
stained positively with safranin-O (Fig. 17A and B). The distribution of GAG was spatially 
uniform throughout the constructs of the IGF-I (50ng/ml) group. Constructs grown in the 
presence of IGFBP-4 appeared histologically partially un-cartilaginous especially at higher 
concentrations (1579 and 15790 ng/mL) with an elevated number of small un-differentiated 
cells (Fig. 17 D and E) and only small amounts of GAG in the core of the construct (Fig. 17 
E) Also, constructs grown in the presence of combinations of IGF-I (50 ng/mL) and IGFBP-4, 
at higher MRs (1:100) appeared histologically partially un-cartilaginous with small 
undifferentiated cells (Fig. 17, G and H) and only a small amount of GAG appeared in the 
core of the construct (Fig. 17 H) 
We can summarize that the addition of IGF-I and IGFBP-4 combinations to the culture 
medium at 1:0.5, 1:1 and 1:3 MR slightly increased construct wet weights and ECM 
components, while at 1:10 and especially at 1:100 MR, the construct wet weights and/or ECM 
components were decreased in comparison to the control group of constructs. When we 
compared these results with the constructs supplemented only with IGF-I, we found that the 
combinations have significant inhibitory effects on the construct wet weights and ECM 
components at all molar ratios.  
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Fig. 17: Glycosaminoglycan (GAG) distribution in histological cross-sections of four week constructs 
grown in culture medium with (A) no supplements, (B) IGF-I 50ng/ml, (C) , IGFBP-4 (15.8 ng/ml) 
(D) IGFBP-4 (1579 ng/ml), (E) IGFBP-4 (15790 ng/ml),(F) 1:1 (IGF-I:IGFBP-4), (G) 1:10 (IGF-
I:IGFBP-4) and (H)1:100 (IGF-I:IGFBP-4). GAG was stained red with safranin-O (dark color in the 
black and white print). (x 100 ). 
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Discussion  
The present study was designed to investigate the effects of IGFBP-4 either in the 
absence or presence of IGF-I on tissue-engineered cartilage grown in a well-established in 
vitro model system (bovine articular chondrocytes dynamically seeded onto biodegradable 
polymer mesh and cultured in medium containing 1% serum) [46;132] with a specific focus 
on the growth rate and ECM components. 
 
IGFBP-4 is the smallest of the six IGFBPs (233 amino acids in rats, 237 amino acids 
in humans). It contains one N-linked glycosylation site and commonly exists in biological 
fluids as a doublet: a 24-kDa non-glycosylated form and a larger 28-kDa glycosylated form 
[133;134]. While IGFBP-4 appears to interact specifically with connective tissues in vivo 
[135], there is no evidence for membrane association of IGFBP-4 in cellular systems, 
suggesting that IGFBP-4 exists primarily as a soluble, extracellular IGFBP.  
 
We studied the effects of IGFBP-4 in the presence and absence of IGF-I on in vitro 
engineered cartilage for the following reasons: Firstly, it has been previously reported that 
IGFBPs inhibit the proliferation and growth rate of many cell types, in vivo and in vitro, 
through the modulation of IGF-I actions [130] and through IGF independent action [136]. 
Secondly, reports indicate that both IGF-I and IGFBPs levels are elevated in the rheumatic 
diseases [137]. Therefore, we investigated the effects of IGFBP-4 both in the presence and 
absence of external IGF-I.  
 
This is the first time that the in vitro effect of IGFBP-4 on tissue-engineered cartilage 
has been studied. Exogenous IGFBP-4 (15.8-15790 ng/ml) in the absence of external IGF-I 
dose-dependently reduced the tissue growth rate and the ECM components of the grown 
constructs. Whereas low concentrations (15.8, 158 ng/ml) did not significantly affect the 
grown tissues, high concentrations (1579, 15790 ng/ml) strongly decreased wet weights and 
amounts of GAG and collagen in the constructs. However, fractions of the ECM components 
per weight were only reduced at the highest concentration (15790 ng/ml). Histological cross-
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sections also revealed strongly decreased GAG amounts at the highest concentration, 
corresponding well with the biochemical analysis.  
In contrast to IGFBP-4, the addition of IGF-I 50 ng/ml into the culture medium of 
engineered cartilage increased the growth rate and ECM deposition, consistent with previous 
results [68;138;139]. IGF-I is one of the most important growth-stimulating factors for 
cartilage, stimulating proliferation and ECM biosynthesis of chondrocytes in vivo and 
cultured chondrocytes and cartilage explants from various species in vitro [68;138;139]. The 
addition of a combination of IGF-I (50 ng/ml) and IGFBP-4 in different MRs into the culture 
medium, however, demonstrated that even at a 1:3 MR, IGF-I can overcome the inhibitory 
effects of IGFBP-4. At the same time, IGFBP-4 can also diminish the stimulatory effects of 
IGF-I. At all molar ratios investigated, the wet weight and the fractions per weight of GAG 
and collagen were reduced when combinations of IGF-I and IGFBP-4 were used, as compared 
to IGF-I alone.  
These results support the concept that IGFBPs may play an important role in the 
regulation of cartilage growth. The logical mechanisms for these effects could be, as 
previously reported, that IGFBPs elicit their effects by their ability to modulate IGF actions 
and by IGF independent action. The findings that IGFBP-4 reduces growth rate and ECM 
content of engineered cartilage may be explained by IGF independent action. Alternatively, 
IGFBP-4 may form complexes with endogenous IGF-I leading either to an inability of IGF-I 
to bind to the type I IGF receptor and/or to the blocking of the receptor by the complex 
[133;134]. 
The results that combinations of IGFBP-4 and IGF-I reduce growth rate and ECM 
content, as compared to IGF-I alone, can be easily explained by reduced concentrations of 
free IGF-I in the medium, as it is sequestrated by complex formation with IGFBP-4. 
Additionally, the formed complex may have blocked the type I IGF receptor rendering it 
inaccessible for exogenous as well as endogenous IGF-I. At high concentrations of IGFBP-4 
(MR 1:10 and 1:100), IGF-I-independent actions of excess IGFBP-4 likely contributed to the 
results. In agreement with our results, to date there have been no reports that IGFBP-4 
enhances IGF-I effects at the cellular level. IGFBP-4 was initially isolated on the basis of its 
inhibition of IGF-stimulated cell proliferation [140]. Furthermore, the ability of IGFBP-4 to 
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inhibit both basal and IGF-mediated chick pelvic cartilage growth in vitro has been reported 
[80]. 
In summary, we have demonstrated that IGFBP-4 had significant inhibitory effects on 
the growth rate and ECM components of in vitro engineered cartilage in the absence of IGF-I. 
When a combination of IGF-I (50 ng/ml) and IGFBP-4 in different molar ratios was applied, 
the inhibitory effects of IGFBP-4 could be overcome by IGF-I even at a 1:3 MR; at the same 
time IGFBP-4 diminished the stimulatory effects of IGF-I.  
 
Summary 
 
The effects of insulin-like growth factor binding protein-4 (IGFBP-4) in the presence 
and absence of external IGF-I on in vitro engineered cartilage were investigated. The specific 
focus was on the ability of IGFBP-4 to influence the growth rate of the constructs and 
concentrations of major extracellular matrix components, i.e., collagen and 
glycosaminoglycans (GAG), and on the effects on the morphological appearance of the tissue. 
Bovine articular chondrocytes were cultured on biodegradable polyglycolic acid (PGA) 
scaffolds in medium with 1% fetal bovine serum (FBS) with and without the addition of 
IGFBP-4 and IGF-I as well as combinations of IGFBP-4 and IGF-I. IGF-I (50 ng/m)l had 
significant stimulatory effects on the engineered cartilage, as compared to control constructs. 
IGFBP-4, in the absence of external IGF-I, had significant inhibitory effects on the 
engineered cartilage compared to control constructs in a dose-dependent manner, as 
demonstrated by an inhibited growth rate, a reduction in the of GAG and collagen production 
and an increased cell number per wet weight. The addition of IGFBP-4 to the engineered 
constructs in the presence of external IGF-I (50 ng/ml) in different molar ratios had 
significant inhibitory effects at all the molar ratios (1:0.5 - 1:100), as compared to constructs 
treated only with IGF-I (50 ng/ml). In contrast, compared to the control group receiving no 
supplemental protein, the combinations showed no inhibitory effects on the growth rate and 
ECM components of the engineered constructs at low IGFBP-4 concentrations (IGF-I: 
IGFBP-4 molar ratio of 1:3), whereas at high concentrations (especially 1:100 molar ratio) 
these parameters were significantly reduced. 
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Introduction 
In cartilage, IGF-I has been identified as one of the major stimulatory factor of 
proteoglycan synthesis [141;142]. Also, it has been reported that IGFs have important role in 
skeletal growth [143] and in the maintenance of mature articular cartilage matrix metabolism 
[144;145]. In recent years, a family of six or more related proteins termed insulin-like growth 
factor binding proteins (IGFBPs) has been discovered that have a high affinity for IGF-I [119-
121]. Their ability to modulate the distribution, function and activities of IGFs in various cell 
tissues and body fluids (either antagonize or augment IGF action) [146;147] points to the 
necessity for understanding this regulatory axis in cartilage.  
 
It has been reported that IGFBP-5 is one of the three predominant IGFBPs (IGFBP-3, 
-4 and -5) produced by articular chondrocytes [125]. However, most of the studies reporting 
on IGFBP-5 have been conducted in bone tissue, where it is acknowledged as the 
predominant IGFBP [148;149]. IGFBP-5 has been suggested to act like a growth factor as it 
stimulates bone formation, at least in part via IGF-independent mechanisms [85;150]. It can 
either inhibit or increase IGF-I effects [83], again in part via an IGF-I-independent 
mechanism [84]. It has been reported that IGFBP-5 is secreted by osteoblast-like cells [151]. 
It is produced as a 252-amino acid protein of about 29 kD [83] and it has IGF-independent 
stimulatory effects in mouse and human osteoblast-like cells [130;152]. Subsequent studies 
have shown that recombinant human IGFBP-5 stimulated DNA synthesis in osteoblasts [152] 
It has been demonstrated that the presence of IGFBP-5 in cell culture medium potentiated the 
growth stimulatory effects of IGF-I on fibroblasts [148]. So far, only a few studies exist that 
have examined the role of IGFBP-5 in cartilage. Increased levels of IGFBPs 2, 3, and 5 were 
detected in the culture media of osteoarthritic compared to normal cartilage; in addition, 
mRNA levels of IGFBPs 3 and 5 were increased in freshly excised diseased cells [126]. The 
concentration of IGFBP-5 in medium conditioned by articular chondrocytes was increased by 
IGF-I in a dose-dependent manner by a transcriptional mechanism via the type 1 IGF receptor 
[153]. Furthermore, it has been reported that the exposure of growth plate chondrocytes to 
IGFBP-5 increased cell proliferation, in the absence or presence of exogenous IGF-I [154]. 
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However, the hypothesis that IGFBP-5 may function as a growth factor in cartilage, as 
shown in bone tissue, has not been evaluated. Therefore, in this study, the effects of IGFBP-5 
were investigated in an established three-dimensional cell culture for the in vitro engineering 
of cartilage. Additionally, the effects of IGFBP-5 in combination with IGF-I were studied. 
The specific focus was on the IGFBP-5 effects on growth and ECM composition of the 
chondrocyte-polymer constructs.  
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Results 
Wet weights  
The wet weights of the cell-polymer constructs after 4 weeks of culture in medium 
containing 1% FBS were significantly increased (1.6, 1.8, and 1.7-fold compared to control) 
with exogenous addition of IGFBP-5 (at 9.5, 95 and 572 ng/ml, respectively). IGFBP-5 at a 
very high concentration (1909 ng/ml) did not affect the wet weight of the cell-polymer 
construct. In the same experiment, the addition of IGF-I at 5 and 50 ng/ml significantly 
increased the wet weights of the construct after 4 weeks of culture to an even higher extent 
(2.6- and 4.8-fold compared to control, respectively) (Fig. 18A). At the same time, the 
addition of a combination of IGF-I (50 ng/ml) and IGFBP-5 at different molar ratios (1:0.5, 
1:1, 1:3 and 1:10) resulted in wet weights of the cell-polymer constructs that were in between 
those of the control and the IGF-I group, i.e., these combinations decreased the wet weights of 
the cell-polymer constructs, as compared to IGF-I (Fig. 18B). (The molecular weight of 
IGFBP-5 is 29 kDa that of IGF-I is 7.6 kDa. Therefore, in order to employ molar ratios of 
1:0.5, 1:1, 1:3, and 1:10, IGFBP-5 concentrations of 95, 190, 572 and 1909 ng/ml had to be 
used in combination with 50 ng/ml of IGF-I (Fig. 18B). Based on these concentrations, the 
concentrations for the experiments employing IGFBP-5 alone were chosen (Fig. 18A)). 
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Fig. 18A: Effects of IGFBP-5 (9.5-1909ng/ml) 
on the wet weight of constructs cultured for four 
weeks. Data represent the average ± SD of three 
constructs. Significance to the control is 
indicated by*, significance between two groups 
is indicated by +. 
Fig. 18B: Effects of IGF-I (50 ng/ml) and IGF-I: 
IGFBP-5 in different molar ratios on the wet 
weight of constructs cultured for four weeks. Data 
represent the average ± SD of three constructs. 
Significance to the control is indicated by* 
significance between two groups is indicated by +. 
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GAG 
The amount of GAG per ww of cell-polymer constructs after 4 weeks culture were 
either slightly decreased (9.5, 1909 ng/ml) or not affected (95, 572 ng/ml) with the exogenous 
addition of IGFBP-5. The addition of IGF-I at 5 ng/ml did also not affect GAG per ww, in 
contrast, 50 ng/ml IGF-I significantly increased the amount of GAG per ww, as compared to 
controls (Fig. 19A). At the same time, the addition of the combination of IGF-I (50 ng/ml) 
and IGFBP-5 at different molar ratios (1:0.5, 1:1, 1:3, and 1:10) significantly decreased the 
amount of GAG per ww of the cell-polymer construct, as compared to IGF-I (Fig. 19B). 
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Fig. 19A: Effects of IGFBP-5 (9.5-1909 
ng/ml) on the fraction of GAG per ww in 
constructs cultured for four weeks. Data 
represent the average ± SD of three 
constructs. Significance to the control is 
indicated by *, significance between two 
groups is indicated by +. 
Fig. 19B: Effects of IGF-I (50 ng/ml) and 
IGF-I:IGFBP-5 in different molar ratios 
on the fraction of GAG per ww in 
constructs cultured for four weeks. Data 
represent the average ± SD of three 
constructs. Significance to the control is 
indicated by *, significance between two 
groups is indicated by +. 
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Collagen 
Exogenous addition of IGFBP-5 (9.5, 95, 572 and 1909 ng/ml) into the culture 
medium increased the amount of collagen per ww of the cell-polymer constructs slightly 
(about 1.3-fold for all concentrations, compared to control), but not significantly at all 
concentrations. The addition of IGF-I at 5 and 50 ng/ml significantly increased the amount of 
collagen per ww (1.5- and 1.9-fold compared to controls, respectively) (Fig. 20A). At the 
same time, the addition of the combinations of IGF-I (50 ng/ml) and IGFBP-5 decreased the 
collagen content per ww of the cell-polymer constructs compared to IGF-I (Fig. 20B); at 
molar ratios of (1:0.5, 1:1 and, 1:3) the amounts of collagen per ww were in between those of 
the control and the IGF-I group, whereas at a molar ratio of 1:10 the values were reduced to 
control levels. 
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Fig. 20A: Effects of IGFBP-5(9.5-1909 ng/ml) 
on the fraction of collagen per ww in 
constructs cultured for four weeks. Data 
represent the average ± SD of three 
constructs. Significance to the control is 
indicated by *, significance between two 
groups is indicated by +. 
Fig. 20B: Effects of IGF-I (50 ng/ml) and 
IGF-I: IGFBP-5 in different molar ratios 
on the fraction of collagen per ww in 
constructs cultured for four weeks. Data 
represent the average ± SD of three 
constructs. Significance to the control is 
indicated by*, significance between two 
groups is indicated by +. 
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Cell number 
The cell number per ww of cell-polymer constructs after 4 weeks culture was not 
significantly affected with the exogenous addition of IGFBP-5 at all concentrations tested. 
The addition of IGF-I significantly decreased the cell number per ww of the construct (56% 
and 38% of control values) (Fig. 21A). At the same time, the addition of the combination of 
IGF-I (50 ng/ml) and IGFBP-5 at different molar ratios (1:0.5, 1:1, 1:3 and 1:10 ) yielded cell 
numbers similar to that of IGF-I alone and significantly lower as control values (47%, 46%, 
50% and 50% of control values) (Fig. 21B ). 
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Fig. 21A: Effects of IGFBP-5 (9.5-1909 
ng/ml) on the cell number per ww of 
constructs cultured for four weeks. Data 
represent the average ± SD of three 
constructs. Significance to the control is 
indicated by *, significance between two 
groups is indicated by +. 
Fig. 21B: Effects of IGF-I (50 ng/ml) and 
IGF-I: IGFBP-5 in different molar ratios 
on the cell number per ww of constructs 
cultured for four weeks. Data represent 
the average ± SD of three constructs. 
Significance to the control is indicated by 
*, significance between two groups is 
indicated by +. 
 
 
Histology 
Safranin-O staining for the detection of the GAG distribution in the constructs after 4 
weeks of culture indicated the following results: control constructs (no protein supplemented) 
stained weakly for GAG; scattered areas stained red for GAG alternated with GAG-depleted 
areas indicated by the green colour which was especially pronounced at the edge of the 
construct (Fig. 22). Compared to controls, cell-polymer constructs supplemented with IGFBP-
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5 exhibited a more coherent tissue formation and relatively high amounts of GAG (Fig. 22.) 
The constructs supplemented with IGF-I showed the strongest staining for GAG. The 
constructs supplemented with combinations of IGF-I and IGFBP-5 exhibited higher amounts 
of GAG than the control, but, at the same time, in these constructs the Safranin-O staining 
appeared to be dose-dependently decreased, as compared to IGF-I constructs (Fig. 22) 
 
            
         
  
         
 
Fig. 22: Glycosaminoglycan (GAG) distribution in histological cross-sections of four week constructs 
grown in culture medium with (A) no supplements (control), (B) IGF-I 50ng/ml, (C) , IGFBP-5 (9.5 
ng/ml) (D) IGFBP-5 (95 ng/ml), (E) IGFBP-5 (1909 ng/ml),(F) 1:1 (IGF-I:IGFBP-5), (G) 1:3 (IGF-
I:IGFBP-5) and (H)1:10 (IGF-I:IGFBP-5). GAG was stained red with safranin-O (dark color in the 
black and white print). (x 100 ). 
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Discussion 
 
This study was conducted to evaluate the hypothesis that IGFBP-5 may function as a 
growth factor in cartilage, as it has previously been suggested for bone tissue [85;150]. The 
experiments were designed to investigate the effects of IGFBP-5 on tissue engineered 
cartilage grown in a well-established in vitro model system. The effects of IGFBP-5 alone or 
in combination with IGF-I on engineered cartilage were studied, focusing on its ability to 
increase tissue growth and the amount of ECM.  
 
Exogenous IGFBP-5 alone clearly stimulated the growth of cartilaginous tissue 
constructs. The amounts of the ECM components GAG and collagen per construct were also 
increased; for collagen even the fraction per wet weight of the constructs was increased. 
Histological cross-sections revealed a more coherent tissue formation after application of 
IGFBP-5, as compared to control constructs; glycosaminoglycans were more evenly 
distributed throughout the sections in IGFBP-5 constructs. Although these significant effects 
of IGFBP-5 were clearly observable, their extent did not equal the results yielded by IGF-I, 
which is known as one of the major growth factors in cartilage and which exerted stronger 
effects in all parameters investigated. In contrast, IGFBP-4 exerted rather detrimental effects 
on tissue-engineered cartilage (see chapter 4) demonstrating within the 3-D culture system 
that IGF binding proteins differentially act on anabolic processes of cartilage. 
 
To date, only few studies exist on direct effects of IGFBP-5 in cartilage tissue 
([126;153;154], see introduction). More data is available on bone tissue, in which IGFBP-5 
has been described to function as a growth factor that stimulates bone formation, at least in 
part via IGF-independent mechanisms [85]. The mechanism by which IGFBP-5 was 
suggested to exert its growth factor effects on osteoblasts involves binding to a specific site 
on osteoblast cell surfaces, i.e., a putative receptor for IGFBP-5 [130;150]. This putative 
receptor is said to be stimulated by IGFBP-5, but not by IGF-I or TGF-ß, thus suggesting that 
the IGFBP-5 putative receptor is functionally different from the IGF-I receptor [155]. Another 
potential mechanism by which IGFBP-5 can exert IGF-independent effects is based on 
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transcriptional activation of genes by IGFBP-5 transported into the nucleus via its nuclear 
localization signal [156]. 
 
IGFBP-5, as the other members of the IGFBP family, has been shown to associate 
with IGF-I under physiological conditions [157]. Consequently, besides its direct effects 
IGFBP-5 may modulate the effects of IGF-I when added into the culture medium in 
combination. An increase of the IGF-I activity by IGFBP-5 may be caused either by targeting 
IGF-I to the receptor-containing cell surface, by an IGF-independent effect of the binding 
protein [158]. 
 
In this study, IGFBP-5 was mixed with IGF-I before the addition into the culture 
medium because the high affinity of IGFBP-5 to ECM structures has been reported to lead to 
an 8-17-fold decrease of the IGFBP-5 affinity for IGF-I [148]. In general, the addition of 
combinations of IGF-I and IGFBP-5 in different molar ratios, into the culture medium of the 
engineered cell-polymer constructs stimulated the growth rate and the formation of ECM 
compared to control; at the same time, these combinations significantly reduced the 
stimulatory effects of IGF-I, i.e., the stimulatory effects on the engineered cartilage resulting 
from this combination were smaller than the stimulatory effects resulting from the addition of 
IGF-I alone. In previous studies, similar results, i.e., that IGFBP-5 can inhibit the stimulatory 
effects of IGF-I have been reported. The addition of a molar excess of IGFBP-5 to cell lines 
that do not secrete IGFBP-5 protease resulted in an inhibition of IGF-I actions [146]. Keifer et 
al showed that IGFBP-5 can inhibit IGF-I stimulation of DNA and glycogen synthesis in 
human osteosarcoma cells [134]. Also, an inhibition of IGF-I-induced steroidogenesis by 
IGFBP-5 in granulosa cells was reported [159]. The mechanism by which IGFBP-5 may 
reduce IGF-I effects was investigated using radiolabelled IGFs in ligand binding assays. It 
was demonstrated that IGFBP-5 is able to inhibit the binding of IGFs to the IGF-I receptor, 
resulting in reduction of receptor stimulation and autophosphorylation [160]. IGFBP-5 
inhibits IGF-stimulated autophosphorylation of the receptor very efficiently and complete 
inhibition was reported to be achieved when IGFBP-5 is present in excess of IGFs [160]. 
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Summary 
This study was conducted to evaluate the hypothesis that insulin-like growth factor 
binding protein-5 may function as a growth factor in cartilage, as it has previously been 
suggested for bone tissue. The effects of IGFBP-5 in the presence and absence of exogenous 
IGF-I on in vitro engineered cartilage were investigated, with a specific focus on the ability of 
IGFBP-5 to influence the growth rate and the composition of the extracellular matrix of the 
cell-polymer constructs. Bovine articular chondrocytes were cultured on biodegradable 
polyglycolic acid (PGA) scaffolds without and with the addition of IGFBP-5 (9.5 -1909 
ng/ml) as well as in combination with IGF-I, in medium with 1% fetal bovine serum (FBS).  
 
Exogenous IGFBP-5 alone clearly stimulated the growth of cartilaginous tissue 
constructs. The fraction of collagen per wet weight of the constructs was slightly increased. 
Histological cross-sections revealed a more coherent tissue formation after application of 
IGFBP-5, as compared to control constructs; glycosaminoglycans were more evenly 
distributed throughout the sections in IGFBP-5 constructs. Though the impact of IGFBP-5 on 
the cartilaginous tissues was obvious, in comparison, IGF-I alone (50 ng/ml) exerted stronger 
effects in all parameters investigated. In combinations with IGF-I, IGFBP-5 generally 
significantly reduced the effects of IGF-I at all molar ratios investigated (1:0.5 – 1:10).  
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Introduction 
A major factor for successful cartilage engineering is the choice of a suitable 3-D 
matrix that can provide the initial structural support and retain cells in the defective area and 
is then degraded when the cells secrete their own matrix. The desirable characteristics of the 
3-D matrix material are biocompatibility, biodegradability, appropriate surface chemistry to 
promote cell attachment, proliferation, and tissue development, and adequate mechanical 
properties to maintain the structure and function after implantation and during the remodelling 
of the implants [53;161;162]. Potential materials with these characteristics include natural and 
synthetic polymers. Although used in many tissue engineering approaches, synthetic polymers 
have the inherent disadvantage that they do not possess a surface which is familiar to the cells 
to support their growth and secretion of extracellular matrix (ECM) [163]. Furthermore, the 
degradation of synthetic polymers often releases toxic [164] or acidic products, such as lactic 
acid from PLLA [164;165], into surrounding tissues, reducing the pH, which may affect 
cellular function [166] and accelerate the degradation rate due to autocatalysis [167]. In 
contrast, among natural polymers are promising candidates to overcome these limitations 
[50;168;169]. For cartilage engineering, collagen, gelatin (denatured collagen), and 
hyaluronic acid appear to be a logical choice, as they are major components of the ECM of 
cartilage. However, scaffolds made from these polymers often lack mechanical stability, the 
scaffold contracts in the culture medium [170;171] leading to reduction in the pore size that 
could restrict cell proliferation and tissue development. Furthermore, in vivo deformation of 
the matrix could result in a loss of contact between the implanted device and the host tissue. 
 
Angele et al. previously introduced a copolymer scaffold made from hyaluronic acid 
and gelatin; the scaffolds allowed for cell proliferation and ECM synthesis indicating their 
potential for cartilage engineering [86]. In order to increase their mechanical stability, 
recently Mueller et al. modified similar scaffolds made from hyaluronic acid, gelatine, and 
collagen type I [87] through the use of selected chemical crosslinking using glutaraldehyde 
(GTA) [172-174], carbodiimides (EDC) [174-176], and genipin [177], respectively. However, 
different crosslinking protocols are reported to possibly exert strong negative effects on 
degradation rate [174;178], cell proliferation [174;176], and biosynthesis [179].  
Chapter 6  New Copolymer Scaffolds 
 
 
__________________________________________________________________________________________ 
- 73 - 
Therefore, the objective of this study was to evaluate the effects of the selected crosslinking 
treatment on the quality of in vitro engineered cartilage. Specifically, we seeded primary 
bovine chondrocytes on different derivatives of these copolymer scaffolds that is either non-
crosslinked or crosslinked using GTA, EDC, or genipin, respectively. Cell-polymer constructs 
were cultivated over 4 weeks in medium containing 1% FBS, either without or with insulin, 
which has been previously demonstrated to improve engineered cartilage [89]. The quality of 
the engineered cartilaginous tissue was assessed on the basis of construct weight, cell number, 
quantitative content of the major ECM components collagen and glycosaminoglycans (GAG), 
and histological and imunohistological staining for ECM components. 
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Results 
Cell adhesion to the scaffolds after seeding 
Determination of the cell number per construct performed after 48 h of seeding, i.e., 
before cultivation, indicated that the chondrocytes adhered to all copolymer scaffolds to a 
similar extent (Fig. 23). Virtually all of the chondrocytes applied in the spinner flask were 
detected on the scaffolds (5 mio cells). The SEM images confirmed that the chondrocytes 
were attached to the surface of the scaffolds as well as showed that in all scaffolds 
chondrocytes appear in the interior of the copolymer scaffold. The latter was especially 
pronounced in EDC crosslinked polymers (Fig. 24). 
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Fig. 23: Effects of crosslinking on the cells which attached to the construct after two days 
seeding in spinner flask with 5 million cells per scaffold in medium with 10% FBS. Data 
represent the average ± SD of 4 independent measurements. Significance between two groups 
is indicated by +. 
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Fig. 24: SEM pictures of cell-polymer constructs after 2 days of seeding in spinner flask in 
cell suspension of 5 million cells per scaffold in medium with 10 % FBS. (a) non-crosslinked 
(b) glutaraldehyde crosslinked (c) genipin crosslinked (d) EDC crosslinked. 
 
Wet weight 
After 4 weeks of cultivation in basal medium containing no insulin (control groups), 
the wet weights (ww) in all groups were comparatively small; among the controls the genipin 
and EDC crosslinked scaffolds yielded the largest weights, i.e., 70 and 57 mg, respectively 
(Fig. 25). The ww of the constructs supplemented with insulin (2.5 µg/ml) were strongly 
increased for all four different scaffolds, especially for the EDC crosslinked group (212 ± 22 
mg) (Fig. 25). Additionally, the macroscopical appearance demonstrating the size of the 
constructs corresponded well with the obtained weights (Fig. 26). 
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Fig. 25: Effects of crosslinking and insulin on the wet weights of cell-polymer constructs 
cultured for four weeks in medium with 1% FBS. Data represent the average ± SD of three 
constructs. Significance to the controls is indicated by *, significance between two groups is 
indicated by +. 
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Fig. 26: Cell-polymer constructs cultured with or without supplemented insulin (2,5 µg/ml)  
after 4weeks of cultivation in medium with 1%FBS (bars indicates 5 mm) 
 
Cell number 
The cell numbers per ww of the constructs in the control groups (no insulin) for the 
non-crosslinked and glutaraldehyde crosslinked scaffolds were 60 and 65 cells/µg, 
respectively. In contrast, distinctly lower cell numbers per construct were determined in the 
control constructs of the genipin and EDC crosslinked groups (35 and 47 cells/µg). The 
numbers of cells per ww found in the insulin-supplemented constructs were clearly decreased 
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(20, 19, 21 and 14 cell/µg), as compared to their controls. (As cell numbers are commonly 
rather high in engineered cartilage, as compared to native tissue, generally smaller cell 
numbers per wet weight are desired in newly developed tissue) (Fig. 27A).  
With regard to total cell number per construct, there were no significant differences between 
all control groups; also between the insulin-supplemented groups, no differences were 
detected. Values for the insulin groups were slightly higher than for controls, the cell numbers 
for all groups were between 2.4 and 3 million cells per construct (Fig. 27B).  
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Fig. 27A: Effects of crosslinking and insulin 
on the cell number per ww of constructs 
cultured for four weeks in medium with 1% 
FBS. Data represent the average ± SD of 
three constructs. Significance to the controls 
is indicated by *, significance between two 
groups is indicated by +. 
Fig. 27B: Effects of crosslinking and insulin 
on the cell number per constructs cultured for 
four weeks in medium with 1% FBS. Data 
represent the average ± SD of three 
constructs. Significance to the controls is 
indicated by *, significance between two 
groups is indicated by +. 
. 
 
Collagen 
In order to assess a possible contribution of the scaffold compounds gelatin and 
collagen type I to the results of the quantitative assay for total collagen, blank scaffolds were 
assayed that had been either not incubated at all or incubated in culture medium for four 
weeks. Whereas unincubated scaffolds resulted in very low absorbance in the UV 
spectrophotometric assay, incubated scaffolds did not result in any reading at all (Fig. 28A).  
After 4 weeks of cultivation, only for the control groups (no insulin) with non-crosslinked 
scaffolds and with glutaraldehyde crosslinked scaffolds a low absorbance was observed (0.51 
** 
** ** 
** 
++ 
Chapter 6  New Copolymer Scaffolds 
 
 
__________________________________________________________________________________________ 
- 78 - 
and 0.38 mg collagen per construct) which was in the same order of magnitude as for the 
blank scaffolds, the values of all other groups were distinctly higher (Fig. 28A). The control 
groups of the genipin and EDC crosslinked copolymer scaffolds showed collagen amounts of 
0.91 and 0.71 mg, respectively (Fig. 28A). The amount of collagen per construct in the 
insulin-supplemented groups was strongly increased in all groups to 3.4, 3.6, 3.6, and 5.2 mg 
per construct for non-crosslinked, glutaraldehyde, genipin and EDC crosslinked derivatives, 
respectively (Fig. 28A).  
With regard to the collagen content, i.e., the percentage of collagen per ww, among the 
control groups, the scaffolds crosslinked with genipin and EDC yielded the highest values 
(1.3 and 1.4 %, respectively (Fig. 28B)). For insulin-receiving groups, the percentages of 
collagen per ww were greatly increased (2.4, 2.3, 2.68, and 2.5 mg), as compared to their 
controls. 
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Fig. 28A: Effects of crosslinking and insulin on 
the collagen fractions per constructs cultured for 
four weeks in medium with 1% FBS. Data 
represent the average ± SD of three constructs. 
Significance to the controls is indicated by *, 
significance between two groups is indicated by 
+. 
Fig. 28B: Effects of crosslinking and insulin on 
the collagen fractions per ww of the constructs 
cultured for four weeks in medium with 1% FBS. 
Data represent the average ± SD of three 
constructs. Significance to the controls is 
indicated by *, significance between two groups 
is indicated by +. 
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GAG 
Theoretically, hyaluronic acid, a major component of the scaffolds, is not detected by 
the quantitative assay for glycosaminoglycans [93]. This was confirmed by assaying scaffolds 
which were not incubated as well as scaffolds which were incubated for four weeks in culture 
medium: No absorbance in the UV spectrophotometric assay was observed in either case. 
In the cultured cell-polymer constructs, after 4 weeks of cultivation in medium containing no 
insulin, the amount of GAG per construct was very low (0.07 and 0.08 mg) for the non-
crosslinked and glutaraldehyde crosslinked copolymer scaffolds and increased for genipin and 
EDC crosslinked copolymer scaffolds (0.6 and 0.2 mg) (Fig. 29A). Also, the percentages of 
GAG per ww were lowest for the non-crosslinked and glutaraldehyde crosslinked copolymer 
scaffolds (0.36 and 0.44 %) and distinctly increased in genipin and EDC crosslinked 
copolymer scaffolds (1.3 and 0.8 %) (Fig. 29B).   
For the insulin-supplemented constructs, the amount of GAG per construct was 
distinctly increased in all groups with the EDC crosslinked group exhibiting the highest value 
(3.86 mg) (Fig. 29A). The percentage of GAG per ww for the insulin-receiving constructs 
was strongly increased, as compared to their controls groups, with genipin and EDC 
crosslinked scaffolds showing the highest content (3.4 and 3.7%) (Fig. 29B). 
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Fig. 29A: Effects of crosslinking and insulin on 
the GAG fractions of constructs cultured for 
four weeks in medium with 1% FBS. Data 
represent the average ± SD of three constructs. 
Significance to the controls is indicated by *, 
significance between two groups is indicated 
by +. 
Fig. 29B: Effects of crosslinking and insulin 
on the GAG per ww of constructs cultured 
for four weeks in medium with 1% FBS. 
Data represent the average ± SD of three 
constructs. Significance to the controls is 
indicated by *, significance between two 
groups is indicated by +. 
** 
** 
** 
** 
++ 
++
++ 
** 
** 
** 
** 
++ 
++ 
Chapter 6  New Copolymer Scaffolds 
 
 
__________________________________________________________________________________________ 
- 80 - 
Histology 
Safranin-O staining also supported the results obtained from the quantitative assay, 
generally indicating the presence of small amounts of GAG in the control constructs of the 
four copolymer scaffolds (Fig. 30). In contrast, the constructs supplemented with insulin 
possessed high amounts of GAG indicated by a strong staining, especially within the EDC 
cross-linked group large coherent areas were detected (Fig. 30). In addition, within the cross-
sections the safranin-O staining indicated for all four control groups only scattered areas of 
coherent tissue formation (Fig. 30). In the insulin-receiving groups, large areas of coherent 
tissue were obtained, especially in the genipin and EDC crosslinked scaffolds. Only in the 
centre of the constructs areas containing only few cells and hardly any ECM were detected, 
especially in the non-crosslinked and glutaraldehyde crosslinked scaffolds (Fig. 30). 
Immunohistochemistry with type I and type II collagen antibodies indicated that 
collagen type I was recognized in very small amounts, especially at the edges of the 
constructs, in all scaffold types, regardless of insulin supplementation. Collagen type II was 
detected in all control constructs in all areas where tissue development was observed; 
however, considerable holes within the cross-sections were also detected. In contrast, collagen 
type II was detected in larger and more coherent areas in the insulin-supplemented groups, 
especially in the genipin and EDC crosslinked scaffolds (Fig. 30). 
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Fig. 30: Histological cross-sections of four week constructs grown in culture medium with 1% FBS: collagen 
type II was stained black with collagen type II antibody, collagen type I was stained black with collagen type I 
antibody, and GAG in ECM was stained red with safranin-O (dark color in the black white and print) (x 100). 
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Discussion  
Scaffolds made from ECM-derived polymers have been repeatedly suggested to serve 
as suitable cell carriers for cartilage engineering [4-6]. The commonly observed disadvantage 
of a low mechanical stability can be overcome by polymer crosslinking. However, serious 
drawbacks, that are impaired cell function and tissue development, have been encountered 
after chemical crosslinking. Therefore, thorough investigations into possible effects of such 
procedures on the quality of engineered cartilage are indispensable. 
 
In this study, we demonstrate that crosslinking of recently developed scaffolds made 
from hyaluronic acid, gelatine, and collagen type I [87] did not impair the development of 
cartilaginous tissues in vitro. Whereas crosslinking using glutaraldehyde resulted in cell-
polymer constructs which were very similar to constructs grown on non-crosslinked scaffolds, 
crosslinking by EDC as well as genipin even resulted in partial improvement of the grown 
constructs. 
 
We seeded bovine chondrocytes on scaffolds made from either non-crosslinked or 
crosslinked copolymers and cultivated them over four weeks in medium containing 1% FBS 
with or without insulin. Cell seeding resulted in no significant differences in cell number 
between the different scaffolds. 
 
After four weeks of cultivation, among the cell-polymer constructs cultured only in 
basal medium (no insulin supplementation), the constructs of the genipin group had the 
largest wet weight and a distinctly higher GAG per weight content than all other groups, the 
EDC group being second. The collagen content of these two groups were only slightly higher 
than that of the non-crosslinked group. Histological cross-sections showed no significant 
differences between all groups receiving basal medium; all constructs exhibited considerable 
amounts of type II collagen and only little amounts of type I collagen, however, coherent 
tissue formation was only detected in scattered areas.  
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In general, all cell-polymer constructs receiving insulin showed a clearly improved 
development of cartilaginous tissue, as compared to the respective groups receiving no 
insulin. The constructs of the insulin-receiving EDC group were considerably larger than 
those of all other groups. The GAG per weight contents were considerably larger in the EDC 
and genipin group than in the group of the non-crosslinked scaffolds, the collagen per weight 
content showed no meaningful differences between all groups. Histological cross-sections 
confirmed the larger ECM content in all insulin-receiving groups. Large areas of coherent 
tissue formation were detected, which was the most pronounced in the EDC and genipin 
group. 
 
The differences between non-crosslinked and crosslinked groups, and the favourable 
effects of crosslinking on the growth rate and on the formation of ECM may, at least in part, 
be explained with previously reported results [180]: Articular chondrocytes produce α-smooth 
muscle actin, enabling them to contract in culture, which was reported to reduce the pore size 
of scaffolds made of collagen and glycosaminoglycans, restricting cell proliferation and 
preventing synthesis of additional type II collagen [29]. Crosslinking was considered to be an 
effective method to minimize the contraction [29]. In addition, the crosslinking of collagen 
with EDC and N-hydroxysuccinimide was shown to be the superior method of crosslinking 
when compared to glutaraldehyde and UV radiation [180]. These findings are well in 
agreement with our study, in which EDC cross-linking yielded advanced tissue development 
as compared to non-cross-linked and glutaraldehyde crosslinked scaffolds. In a study 
employing acellular biological tissue made from bovine pericardia, genipin was used as a 
crosslinker [181] Tissue ingrowth after in vivo implantation was observed demonstrating the 
general usefulness of genipin in tissue engineering applications, again in agreement with the 
results obtained with cartilage in the present study.  
 
In summary, the hyaluronic acid-gelatine-collagen copolymer scaffolds, especially 
when crosslinked using EDC, appear to be suitable candidates for cartilage engineering. 
Under favourable conditions employing insulin as potent effector molecule almost the 
complete cross-section exhibited well-developed cartilaginous tissue, demonstrating that the 
process of crosslinking can be advantageous for cartilage engineering. Future studies should 
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be undertaken to further improve tissue development also in the very centre of the constructs, 
possibly by altering scaffold pore size and interconnectivity. 
 
 
Summary 
The scaffold used in the process of cartilage engineering is considered as one of the 
most important factors affecting the quality of the engineered tissue. Scaffolds made from 
natural polymers appear to be useful candidates as they can provide a similar matrix as 
present in native tissue. As scaffolds made from natural polymers often lack mechanical 
stability, chemical crosslinking can be employed in order to improve the mechanical 
performance. However, crosslinking has been reported to have serious disadvantages with 
regard to cellular function and tissue development. Therefore, it is indispensable to investigate 
into the effects on tissue quality exerted by the employed crosslinking procedures. 
Recently, a new natural biodegradable copolymer scaffold has been developed 
consisting of hyaluronic acid, gelatin, and collagen [87]. Within this study, scaffolds made 
from different derivatives of this copolymer, that is non-crosslinked, genipin crosslinked, 
EDC crosslinked and glutaraldehyde crosslinked, were investigated with regard to their 
suitability for in vitro cartilage engineering. Scaffolds were seeded with bovine chondrocytes; 
the seeding efficiency was found to be equal for all scaffolds. Cell-polymer constructs were 
cultivated in medium containing 1% fetal bovine serum (FBS) over four weeks without and 
with insulin supplementation. Thereafter, the weight, size and shape of each construct were 
evaluated and the amount of extracellular matrix (ECM) and the cell number were estimated. 
In addition, GAG and collagen types I and II were detected histologically and 
immunohistologically.  
It was demonstrated that neither of the crosslinking procedures impaired the 
development of cartilaginous tissues In general, whereas crosslinking using glutaraldehyde 
resulted in cell-polymer constructs which were very similar to constructs grown on non-
crosslinked scaffolds, crosslinking by EDC as well as genipin even resulted in partial 
improvement of the grown constructs. The most advanced cell-polymer constructs were those 
grown on EDC crosslinked scaffolds in the presence of insulin. They exhibited a distinctly 
Chapter 6  New Copolymer Scaffolds 
 
 
__________________________________________________________________________________________ 
- 85 - 
larger wet weight and larger glycosaminoglycan content per weight, and larger areas of 
coherent ECM and tissue formation, as compared to the non-crosslinked scaffolds.  
The study suggests the scaffolds made from hyaluronic acid, gelatine, and collagen, and 
crosslinked with EDC as suitable candidate for cartilage engineering. 
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Introduction 
Most of the research on the generation of engineered cartilage has focused on (a) the 
cell carrier, i.e., the nature, the quality and the method of preparations of scaffolds 
[39;40;55;56;62;182;183], (b) the effects of exogenous growth factors on chondrocyte 
proliferation and ECM synthesis [68;73;89;95;184-190], (c) the effects of physical stimuli on 
extracellular matrix synthesis [94;191-193], and (d) the cell source (mainly chondrocytes or 
mesenchymal stem cells) and the possibility of expanding the cells in order to obtain a 
sufficient number of cells to graft or to seed in a scaffolds [49;194-196]. However, most of 
the studies have investigated these parameters in a short term culture (two - six weeks) and up 
to now only very few studies were conducted to study the effects of long-term culture on 
engineered cartilage.  
 
It has been reported that some of the most age-related changes in articular cartilage in 
adult humans and animals are an increase in the degradation of matrix components [197]. and 
a decrease in the number of chondrocytes [198] Calcification occurs in the ECM of the 
hypertrophic zone of the growth plate, the ECM volume is reduced to a minimum and alkaline 
phosphatase content is maximal [199]. Total collagen initially increases through the 
proliferating and maturing zones but then rapidly decreases in the hypertrophic zone [199]. 
Chondrocyte play a signalling role in the determination of bone growth through their function 
in the endochondral ossification process [200]. In this process the avascular cartilage template 
is replaced with a highly vascularized, mineralized tissue. In addition, hypertrophic 
chondrocytes secrete matrix vesicles containing enzymes that actively degrade and mineralize 
their surrounding matrix [201]; these cells undergo apoptosis as this area is invaded by blood 
vessels, osteogenic cells and mesenchymal precursors. The residual calcified cartilage matrix 
act as scaffolds for the deposition of mineralized bone matrix, resulting in the production of 
new trabecular bone [202;203]. 
 
The purpose of this experiment was the monitoring of the effects of in vitro ageing on 
engineered cartilage. Bovine chondrocytes were seeded on PGA scaffolds and the cell-
polymer constructs were cultivated in medium containing 1% FBS for up to 16 months with 
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and without insulin. We focused on the extracellular matrix content and the calcification of 
the engineered cartilage after long-tem in vitro culture. 
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Results 
Time course of tissue development 
 In this study conducted large PGA meshes (6 x 8 mm, 2 mm thick) were seeded with 
chondrocytes. Two separate studies were performed; in the first one, large scaffolds were 
cultivated and harvested at four different time points, that is, after 1, 4 , 8, and 12 months in 
order to evaluate the time course of tissue development. In the second experiment, scaffolds 
were harvested only after 16 months, mainly to investigate calcification of the tissue.  
This study was planned as a preliminary investigation.Therefore, only one large construct was 
used per group. Parts of the construct were used for histology, other parts were used for GAG, 
collagen, and cell number assays. Standard deviations in the GAG, collagen, and cell number 
assays result from the investigation of two different parts of the construct. 
 
First, the growth rate of cell-polymer constructs cultured in medium containing 1% 
FBS either supplemented with insulin (2.5 µg/ml) or without insulin was monitored. The cell-
polymer constructs strongly and continuously increased in size and weight over the course of 
12 months of in vitro culture. After one month the wet weights were 232 mg (without insulin) 
and 508 mg (with insulin), after 4 months the cell-polymer constructs had grown to 474 mg 
and 1877 mg, after eight months the weights were 1090 mg and 3500 mg (see also Fig. 31) 
and after twelve months the weights were (1667 mg and 4660 mg) (Fig. 32). 
 
In the second study, cell-polymer constructs harvested after 16 months were smaller 
and the weights of the constructs were 940 mg and 2600 mg without and with insulin 
supplementation, respectively (Fig. 32). 
 
Macroscopically, at four months and thereafter the appearance of the cell-polymer 
constructs highly resembled that of native cartilage, i.e., glossy and white (Fig. 31A). 
However, also at four months, there was a zone recognizable in the middle of the construct 
cross-sections that appeared slightly darker and, upon gross examination using forceps and 
scalpel, mechanically weaker (Fig 31B).  
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Fig. 32: Wet weights of the constructs at different points of time of in vitro culture. Medium 
contained 1% FBS with and without insulin. 
 
Cell number 
The cell number per wet weight of the constructs cultured for four months with or 
without insulin was highly decreased, as compared to after one month (67 and 36 per µg 
 
 
Fig. 31: Cell-polymer construct after 8 months culture in medium containing 1% FBS 
and supplemented with insulin (2.5 µg/ml). A: Whole construct.  B: Cross-section. 
A B 
first study second study 
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without insulin, 34 and 23 per µg with insulin). After that the cell numbers per weight did not 
change significantly (Fig. 33), it was always lower in insulin constructs, as compared to the 
constructs receiving no insulin. 
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Fig. 33: Cell number per wet weight of the constructs at different points of time of in vitro 
culture. Medium contained 1% FBS with and without insulin 
 
ECM quantification 
GAG 
The amount of GAG per wet weight increased in constructs supplemented either with or 
without insulin up to eight months. After one month the amount of GAG per wet weight in 
both groups (with and without insulin) was about 3.8% and after four months about 6%. 
However, after eight months GAG per weight was 7.6% for the construct without insulin and 
10% for the construct with insulin. After one year in culture the amount of GAG per wet 
weight was hardly changed in the group without insulin (6.8%) and decreased in the group 
supplemented with insulin (to 7%) (Fig. 34). 
first study second study 
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In the second study, after sixteen months the amount of GAG per wet weight was very 
low in the construct without insulin (3%), the insulin-supplemented construct had about 6% 
(Fig. 34). 
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Fig. 34: GAG per wet weight of the constructs at different points of time of in vitro culture. 
Medium contained 1% FBS with and without insulin. 
 
 
Total collagen 
The amount of collagen per wet weight of the constructs increased in both the insulin-
receiving group and in the group without insulin over the whole course of the experiment. 
After 1 month the collagen content was about 2% in both groups and after 12 months it was 
6.1% in the non-insulin group and 8% in the insulin-receiving group. (Fig. 35).  
In the second study, after 16 month also high values were reached, i.e., 7.4% in the non-
insulin group and 8.1% in the insulin-receiving group (Fig. 35). 
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Fig. 35: Collagen per wet weight of the constructs at different points of time of in vitro 
culture. Medium contained 1% FBS with and without insulin. 
 
 
Histology 
GAG 
The histological staining with safranin-O for the detection of GAG distribution throughout 
the constructs confirmed the results obtained in the biochemical assay. After one month, the 
construct without insulin exhibited a considerable amount of GAG but with large holes in the 
cross-sections (Fig. 36). After four months, cross-sections of these constructs also contained 
large areas with GAG, but also GAG-depleted regions preferentially at the edges; in addition, 
the chondrocytes in the GAG-containing areas appeared more rounded than after one month 
(Fig. 36). After eight and twelve months the staining for GAG appeared even more intensive 
and continuously distributed throughout the whole constructs (Fig. 36). 
The insulin-supplemented group, after one month, contained a considerable amount of 
GAG. The amount of GAG was increased after four and eight months, when an intensive red 
staining was observed and chondrocytes appeared large and rounded and lay in lacunae. At 
one year, whereas the inner area of the cross-section appeared similar to the constructs at 
earlier time points, there was a large outer area in the cross-section which contained little 
GAG (pink color) and hardly any cells in lacunae (Fig. 36).  
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In the separate study after sixteen months, the amount of GAG in the non-insulin group 
appeared very small and poorly distributed throughout the construct. There were different 
zones observable within the cross-section: The first zone at the constructs edge appeared 
completely depleted of GAG and contained a very small number of cells, the second zone 
contained cells surrounded by matrix stained with green or pink colour, and the third zone 
contained large, rounded chondrocytes embedded in little GAG, indicated by the light red 
staining (Fig. 36). In the insulin-receiving group, after sixteen months, the cross-sections were 
similar as at twelve months in the first study, only the area at the very edge of the construct, 
which was depleted of GAG and was also observed at all time points before, was even thicker 
and more obvious, which was similar to the non-insulin group (Fig. 36). 
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Fig. 36: Histological cross-sections of constructs grown in culture medium with 1% FBS. 
GAG in extracellular matrix was stained red with safranin-O (dark color in the black and 
white print) (x 100). 
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Collagen type II and type I 
Collagen type II, a marker for differentiated chondrocytes, was detected at high levels in 
all constructs either supplemented with insulin or without insulin. The chondrocytes appeared 
large, i.e. probably hypertrophic, especially after 4, 8, and 12 months (Fig. 37). Collagen type 
I was clearly detected, at all time points, at the surface of the constructs supplemented either 
with or without insulin, corresponding to the flat, elongated fibroblast-like cells (Fig. 37).  
In the second study, after sixteen months of in vitro culture, the zone at the edge of the 
cross-section that stained dark with collagen type I antibody was broader corresponding to the 
broad GAG-depleted areas observed in the Safranin-O stain (Fig. 37).  
 
Calcification 
Von Kossa staining for the detection of calcium phosphate as black spots in the 
construct cross-sections revealed that there was no calcium phosphate in both groups of 
constructs, either with or without insulin, at 1, 4, 8, and 12 months of cultivation.  
In contrast, in the second study after sixteen months, in the cross-sections of constructs 
supplemented with insulin there were small spots stained with black colour beneath the 
superficial zone. In the non-insulin group, the black spots appeared more intensive and were 
more widely spread into the constructs (Fig. 38). 
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Fig. 37: Immunohistological staining of cross-sections of constructs grown in culture medium 
with 1% FBS. Collagen type II (first and second row) and type I (third and fourth row) was 
stained dark brown with collagen type II and type I antibodies (dark color in the black and 
white print) (x 100). 
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Fig. 38: Von Kossa staining of cross-sections of constructs grown in culture medium with 1% 
FBS at two time points. Calcified zones stained black (x 100 or x 40) 
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Discussion  
This study was performed to evaluate the effects long-term in vitro culture on tissue-
engineered cartilage grown in a well-established in vitro model system with and without 
insulin. It focused on the growth rate, the amount of ECM, cell number and the calcification 
of the engineered cartilage. So far, many studies have been undertaken investigating 
parameters affecting engineered cartilage in a short term culture (mainly two to six weeks), 
however, few data exist on long-term engineering culture. Here, two separate studies were 
performed; in the first one, tissue constructs were harvested after 1, 4, 8, and 12 months, and 
in the second study the constructs were harvested after 16 months. 
 
The first study illustrated that it is possible to culture tissue-engineered cartilage over 
one year. The results obtained after 1, 4, 8, and 12 months showed that the cartilage grown 
without insulin (control) continuously increased throughout this period of in vitro culture in 
weight and size; also high amounts of the ECM components GAG and collagen were 
accumulated. At the same time, exogenous addition of insulin dramatically increased 
construct weight and size, as compared to the control constructs, and even increased fractions 
per weight of GAG and collagen (10% GAG and 8% collagen, compared to 8% GAG and 6% 
collagen of control constructs, after 8 and 12 months, respectively). All constructs contained 
type II collagen in abundance, as determined by immunohistochemistry; type I collagen was 
mainly detected in thin areas at the edges of the construct cross-sections. Especially after 4, 8, 
and 12 months enlarged cells appeared which had likely undergone hypertrophy. Previous 
studies have shown that chondrocytes undergo hypertrophy in vitro and express a number of 
bone factors that contribute to bone formation [204]. In constructs of both groups, after four 
month, a zone was recognized at the construct core that appeared mechanically weaker upon 
gross examination. Due to the large construct size, a lack of nutrient diffusion and/or oxygen 
supply possibly contributed to this phenomenon.  
 
The second study used cells from a different cell isolation and results were only 
obtained after sixteen months. The constructs were smaller than the ones of the first study 
after twelve month. Insulin-receiving constructs contained similar fractions of GAG and 
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collagen than constructs of the first study, whereas control constructs contained smaller GAG 
fractions and larger collagen fractions. Differences between the studies can likely be 
attributed to different primary cell material. The most important results in this study is the 
development of scattered zones of calcification in the constructs. Von Kossa staining 
demonstrated that these zones were rich in calcium; at the same time very small amounts of 
GAG and collagen type II were detected with safranin-O stain and collagen type II antibody, 
respectively. The calcified zones appeared more intensive and more widely spread into the 
construct receiving no insulin, as compared to the insulin-receiving construct. This finding 
may be explained by insulin keeping the chondrocytes in the differentiated state, i.e., 
synthesizing cartilage-specific ECM, GAG and collagen. Thus, it may have minimized the 
calcification of the engineered cartilage in this experiment. Additionally, insulin may have 
been suppressing the release of proteases such as MMPs which can play a major role in the 
ossification process.  
 
It has been reported that in vivo after terminal differentiation of chondrocytes into the 
hypertrophic state, these chondrocytes secrete large amounts of a specialized matrix rich in 
collagen type X, as well as some proteases such as matrix metalloproteinase (MMPs) 
[205;206]. MMPs can cleave ECM components and may facilitate mineralization; the absence 
of these proteases resulted in an enlargement of the hypertrophic zone and subsequent delay 
of the ossification process [202].In the future, further studies would be valuable that 
investigate the levels of proteases such as MMPs in engineered cartilage in order to decide if 
the calcification of the engineered cartilage after long-term in vitro culture resulted from the 
elevation of these enzymes or not. Also, further studies are needed to detect the distribution of 
collagen type X as a marker for the hypertrophic zone. 
 
The results of this study raise questions, if the development of the calcified zones in 
the engineered cartilage after long-term culture is to be regarded as a positive or negative 
effect and also if similar effects will appear in vivo after implantation of such constructs. The 
latter may lead to serious problems in zones where pure cartilaginous tissue is required. 
Therefore, further research has to be conducted into possibilities to avoid undesired 
calcification of engineered cartilage. For other applications, these properties of the constructs 
Chapter 7  Long-term in vitro Culture 
 
 
__________________________________________________________________________________________ 
- 101 - 
may be turned into an advantage. Case et al (2003) studied the ability of tissue engineered 
cartilage constructs to support bone formation. They seeded articular chondrocytes onto PGA 
disks, cultured for 4 weeks in vitro, and then transferred them to empty bone chambers 
previously implanted into rabbit femoral metaphyses. After 4 weeks in vivo, the result 
demonstrated that tissue-engineered cartilage constructs implanted into a well-vascularized 
bone defect will support direct appositional bone formation [207]. One can consider the 
results of our experiment as positive if it is hypothesized that after implantation of such a 
construct into a cartilage defect at the junction between the engineered cartilage and the host 
bone tissue it will perform the same physiological functions (endochondral ossification) of 
native cartilage, especially in children, to promote normal bone development and maintain 
longitudinal bone growth. However, further studies are needed to evaluate this hypothesis. 
 
 
Summary  
 The objective of this study was to evaluate the effects of long-term in vitro culture on 
tissue-engineered cartilage with and without insulin focusing on the amount of ECM and the 
calcification of the engineered cartilage. In two separate studies bovine articular chondrocytes 
were seeded on polyglycolic acid scaffolds in spinner flask for two days, after which cell-
polymer constructs were transferred into 6-well plates. In the first study, constructs were 
cultured for up to 12 months in medium containing 1% FBS either with or without exogenous 
insulin; the cell-polymer construct were harvested after 1, 4, 8, and 12 months. In the second 
study, the cell-polymer constructs were cultured at the same condition and harvested after 16 
months.  
 
The monitoring of in vitro engineered cartilage for 12 months in the first study 
revealed that the engineered tissues grew continuously and contained high amounts of ECM. 
Insulin-receiving constructs were dramatically larger in size and contained larger fractions of 
GAG and collagen (up to 10% and 8%, respectively). Type II collagen was detected in 
abundance in all constructs. In the second study, after sixteen months of in vitro culture, 
scattered zones of calcification developed in the engineered cartilage, especially in constructs 
cultivated without insulin. Future studies may investigate the events associated with 
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chondrocytes within the constructs undergoing hypertrophy and calcification of the 
constructs. Furthermore it appears important to evaluate the long-term performance of tissue 
engineered cartilage in vivo in dependence of the implantation site.  
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Summary and Conclusions 
 
Tissue engineering of cartilage holds the promise to improve treatment strategies to 
overcome the problems arising from the loss or failure of tissue occurring through diseases or 
accidents. Engineered cartilage is considered to be one of the first engineered tissues that will 
reach a broad market. The optimization of the in vitro culture conditions to get an ideal tissue, 
highly resembling native tissue, is a very important step in the process of tissue engineering. 
The goal of this thesis was to study different factors affecting the development of in vitro 
engineered cartilage. 
Chondrocytes were seeded on synthetic or natural biodegradable scaffolds. Then the 
cell-polymer constructs were cultivated over different periods of time to develop a cartilage-
like tissue. The cells proliferated and produced ECM molecules, at the same time the polymer 
scaffolds degraded. After the in vitro culture period, the cell-polymer construct was 
biochemically, histologically and immunohistochemically investigated. In the period of in 
vitro culture the effects of exogenously applied cytokines and growth factor binding proteins 
(IGFBPs) on the growth rate and content of ECM components (glycosaminoglycans (GAG) 
and collagen) of the engineered cartilage were analyzed (chapter 3, 4 and 5); investigations 
into the mechanism of action of interleukin-4 (IL-4) was conducted (chapter 3). Furthermore, 
the potential of new natural biodegradable copolymer scaffolds to generate cartilage-like 
tissue was evaluated (chapter 6). An additional experiment was designed to monitor the 
development of in vitro engineered cartilage for 16 months with a special focus on the ECM 
components and a possible calcification of the engineered cartilage (chapter 7). 
 
Interleukin-4 was investigated in order to evaluate its potential to improve the quality 
of engineered cartilage (chapter 3). IL-4 was previously shown to inhibit degradation of 
proteoglycans, a major component of cartilage ECM [75], through mechanisms of action are 
still controversially discussed [75;103-106]. In the present study, IL-4 had positive effects on 
the growth rate, ECM composition, and GAG distribution of the engineered cartilage. Thus, 
IL-4 appeared as promising candidates to improve the development and composition of 
engineered cartilage. The mechanism by which IL-4 increases the GAG content may be either 
inhibition of GAG degradation or increased GAG subtype synthesis. In order to elucidate the 
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respective contributions, RT-PCR was employed to investigate the expression of (1) matrix 
metalloproteinases MMP-1, MMP-3, MMP-13; (2) tissue inhibitor of metalloproteinases-1 
(TIMP-1); and (3) GAG subtypes aggrecan and biglycan. Whereas effects of IL-4 on MMP-1, 
MMP-3 and TIMP-1 expression have been suggested previously, this study was the first to 
evaluate the effects of IL-4 on MMP-13 expression. IL-4 was demonstrated to have distinct 
inhibitory effects on MMP-13 expression without significantly affecting any of the other 
factors investigated (slight increase of MMP-3 and decrease of aggrecan). Our results suggest 
that IL-4 increases GAG fractions in engineered cartilage at least in part by decreasing MMP-
13 expression and thus inhibiting GAG degradation. 
Insulin-like growth factors binding proteins (IGFBPs) are a family of six or more 
related proteins that affect the growth rate of cartilage, have a high affinity for IGF-I [119-
121] and modulate its actions [76;77]. They have been detected in the culture media of 
cultured chondrocytes from various species [78;79] and in intact bovine cartilage [124]. In 
chapter 4, the hypothesis that IGFBP-4 inhibits the growth of cartilage in absence of IGF-I 
was evaluated in a well-established 3-D culture system. In addition, the inhibitory effects of 
IGFBP-4 on the actions of IGF-I, which has potent stimulatory effects on chondrocyte 
proliferation and extracellular matrix synthesis [68], were investigated. The results 
demonstrated that exogenous IGFBP-4, in the absence of exogenous IGF-I, had significant 
inhibitory effects on the engineered cartilage compared to control constructs in a dose-
dependent manner, as demonstrated by an inhibited growth rate, a reduction in the GAG and 
collagen production and an increased cell number per wet weight. The addition of IGFBP-4 to 
the engineered constructs in the presence of exogenous IGF-I (50 ng/ml) in different molar 
ratios had significant inhibitory effects at all molar ratios (1:0.5 - 1:100), as compared to 
constructs treated only with IGF-I (50 ng/ml). In contrast, compared to the control group 
receiving no supplemental protein, the combinations showed no inhibitory effects on the 
growth rate and ECM components of the engineered constructs at low IGFBP-4 
concentrations (IGF-I: IGFBP-4 molar ratio of 1:3), demonstrating that IGF-I can overcome 
the inhibitory effects of IGFBP-4. 
 
IGFBP-5 is expressed by chondrocytes [81;82] and is the predominant IGFBP in bone 
[148] where it can either inhibit or increase IGF-I effects [83], in part via an IGF-I-
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independent mechanism [84]. The hypothesis that insulin-like growth factor binding protein-5 
may function as a growth factor in cartilage, as it has previously been suggested for bone 
tissue [85], was evaluated in chapter 5. The effects of IGFBP-5 on in vitro engineered 
cartilage were investigated in the presence and absence of exogenous IGF-I. The results 
demonstrated that exogenous IGFBP-5 in absence of IGF-I clearly stimulated the growth of 
cartilaginous tissue constructs. The fraction of collagen per wet weight of the constructs was 
slightly increased. Histological cross-sections revealed a more coherent tissue formation after 
application of IGFBP-5, as compared to control constructs; glycosaminoglycans were more 
evenly distributed throughout the sections in IGFBP-5 constructs. Though the impact of 
IGFBP-5 on the cartilaginous tissues was obvious, in comparison, IGF-I alone (50 ng/ml) 
exerted stronger effects in all parameters investigated. In combinations with IGF-I, IGFBP-5 
generally significantly reduced the effects of IGF-I at all molar ratios investigated. 
 
Scaffolds made from natural polymers appear to be useful candidates for tissue 
engineering purposes as they can provide a similar matrix as present in native tissue. 
Recently, a new natural biodegradable copolymer scaffold has been developed consisting of 
hyaluronic acid, gelatin, and collagen [87]. In order to improve mechanical stability of 
scaffolds made from natural polymers, chemical crosslinking can be employed [175-177]. 
However, as chemical crosslinking processes may lead to cell toxic effects or impairment of 
tissue development [174;175], such scaffolds have to be carefully investigated in cell culture. 
In chapter 6, scaffolds made from different derivatives of this copolymer, that is non-
crosslinked, genipin-crosslinked, EDC-crosslinked and glutaraldehyde-crosslinked, were 
investigated with regard to their suitability for in vitro cartilage engineering. The results 
revealed that the seeding efficiency was found to be equal for all scaffolds after seeding with 
chondrocytes for two days. After 4 weeks of cultivation without and with insulin 
supplementation the results demonstrated that neither of the crosslinking procedures impaired 
the development of cartilaginous tissues. In general, whereas crosslinking using 
glutaraldehyde resulted in cell-polymer constructs which were very similar to constructs 
grown on non-crosslinked scaffolds, crosslinking by EDC as well as genipin even resulted in 
partial improvement of the grown constructs. The most advanced cell-polymer constructs 
were those grown on EDC crosslinked scaffolds in the presence of insulin. They exhibited a 
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distinctly larger wet weight and larger glycosaminoglycan content per weight, and larger areas 
of coherent ECM and tissue formation, as compared to the non-crosslinked scaffolds.  
 
Many studies on in vitro engineering of cartilage have been conducted; however, most 
of those studies have been conducted in short-term cultures, that is, over two to six weeks. 
Hardly any data exist on long-term in vitro culture so far. Therefore, in chapter 7 the 
development of engineered cartilage was monitored in two separate studies over 12 and 16 
months, respectively. In the first study, the engineered tissues grew continuously over one 
year and contained high amounts of ECM. Insulin-receiving constructs were dramatically 
larger in size and even contained larger fractions of GAG and collagen (up to 10% GAG and 
8% collagen). Type II collagen was detected in abundance in all constructs. In the second 
study, after sixteen months of in vitro culture, scattered zones of calcification developed in the 
engineered cartilage, especially in constructs cultivated without insulin. Future studies may 
investigate the events associated with the chondrocytes undergoing hypertrophy and the 
calcification of the constructs. Furthermore it appears important to evaluate the long-term 
performance of tissue engineered cartilage in vivo in dependence of the implantation site. 
 
To conclude, this thesis contributed to the development of strategies for engineering 
cartilage tissues. Specific bioactive molecules (IL-4, IGFBP-5) were demonstrated to enhance 
the quality of engineered cartilage; another protein (IGFBP-4) was shown to reduce the 
growth rate and compromise the quality of engineered cartilage. Additionally, a novel 
mechanism of action of IL-4 in cartilage was suggested. All of these studies also 
demonstrated the employed 3-D engineering culture as a useful model to investigate the 
effects and/or mechanisms of specific molecules in developing cartilage. The potential of 
novel scaffolds made from natural crosslinked copolymers to generate new cartilage was 
illustrated. Furthermore, the effects of long-term in vitro culture up to 16 months on 
engineered cartilage were monitored, proving, on the one hand, the feasibility of generating 
tissue constructs with high ECM content, but, on the other hand, showing calcification of the 
constructs and contributing to the discussion about the potential applications of such tissues in 
vivo. 
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Abbreviations 
 
3-D  three-dimensional 
ANOVA analysis of variance 
AT   annealing temperature 
BSA  bovine serum albumin 
cDNA  complementary deoxyribonucleic acid 
CLD  crosslinked 
CS  chondroitin sulfate 
DAB   diaminobenzidine 
DMEM  Dulbecco´s Modified Eagle´s Medium 
DNA   deoxyribonucleic acid 
ECM  extracellular matrix 
EDC  carbodiimides 
exog.   exogenous 
FBS   fetal bovine serum 
FCS  fetal calf serum 
GAG   glycosaminoglycans 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GTA  glutaraldehyde 
H&E   hematoxylin and eosin 
HEPES  N-2-hydroxyethylpiperazine N'-2-ethanesulfonic acid  
IGD  interglobular domain 
IGFBP-4  insulin-like growth factor binding protein-4 
IGFBP-5  insulin-like growth factor binding protein-5 
IGF-I   insulin-like growth factor-I 
IL-1  Interleukin-1 
IL-1RI  IL-1 type 1 receptor  
IL-4  interleukin-4 
kDa  kilodalton 
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MMP   matrix metalloproteinase 
MMP-1 matrix metalloproteinase-1 
MMP-13  matrix metalloproteinase-13 
MMP-3  matrix metalloproteinase-3 
MW  molecular weight 
NMR   nuclear magnetic resonance 
OsO4  osmium tetroxide  
PBS   phosphate buffered saline 
PCR  polymerase chain reaction 
p-DAB  p-dimethylaminobenzaldehyde 
PGA  polyglycolic acid 
PLA   polylactic acid 
RNA  ribonucleic acid 
rpm   rotations per minute 
rRNA   ribosomal ribonucleic acid 
RT-PCR  reverse transcription polymerase chain reaction 
SD   standard deviation 
SEM  scanning electron microscopy 
TE   tissue engineering 
TIMP-1  tissue inhibitor of metalloproteinase-1 
TNFα  tumor necrosis factor α 
UV   ultraviolet light 
ww   wet weight 
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